← Back to search
7jfl

Crystal structure of human phosphorylated IRF-3 bound to CBP

Method: X-RAY DIFFRACTION Dmax: 76.9 Å Quality: EXCELLENT
▼

1. Protein Identity and Related Structures Protein Identity & Related Structures

Interferon regulatory factor 3

Homo sapiens

UniProt Q14653

State in the Current Structure

Assembly Oligomeric State Construct Mutations and Modifications Ligands, Ions and Associated Components Method and Experimental Conditions Structure Quality
1 Protein heterocomplex Heteromer Protein × 4 PDB declaration: tetrameric（4） Consistent with protein copy count Chain A； UniProt 189–398 Chain B； UniProt 189–398 Non-standard monomer：Yes (specific site not provided by mmCIF) CREB-binding protein × 2 （Q92793） X-RAY DIFFRACTION X-ray crystallization conditions：VAPOR DIFFUSION, HANGING DROP；pH 5；277 K；0.1 M sodium acetate pH 5.0, 0.2 M MgCl2, 5% PEG 3350 Resolution 1.68 Å R-free 0.223

Other States of the Same Protein in the Database

Each row is a biological assembly of the same UniProt protein in another PDB entry. The “Difference from current entry” column identifies evidence-level differences; no tag means the currently parsed fields agree.

Other PDB Difference from Current Entry 7JFL Assembly / Oligomeric State Construct Mutations and Modifications Ligands, Ions and Non-polymers Method and Experimental Conditions Structure Quality
1J2F X-ray crystal structure of IRF-3 and its functional implications Deposited 2003-01-04 Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 175–427（253 aa） Fragment：residues 170-427
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 4.2；277 K；magnesium formate, pH 4.2, VAPOR DIFFUSION, SITTING DROP, temperature 277K
Resolution 2.30 Å R-free 0.242
1J2F X-ray crystal structure of IRF-3 and its functional implications Deposited 2003-01-04 Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 175–427（253 aa） Fragment：residues 170-427
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 4.2；277 K；magnesium formate, pH 4.2, VAPOR DIFFUSION, SITTING DROP, temperature 277K
Resolution 2.30 Å R-free 0.242
1QWT Auto-inhibitory interferon regulation factor-3 (IRF3) transactivation domain Deposited 2003-09-03 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 173–427（255 aa）
Chain B 173–427（255 aa）
Not recorded PO4 PHOSPHATE ION × 8 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.10 Å R-free 0.214
1T2K Structure Of The DNA Binding Domains Of IRF3, ATF-2 and Jun Bound To DNA Deposited 2004-04-21 Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 1 Protein–DNA Heteromer；Protein × 4 PDB declaration: hexameric
Chain A 1–112（112 aa） Fragment：N-terminal DNA binding domain
Chain B 1–112（112 aa） Fragment：N-terminal DNA binding domain
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.5；295 K；100 mM NaCacodylate, pH 6.5, 12.5% (w/v) PEG 6000, 400 mM NH4OAc, VAPOR DIFFUSION, HANGING DROP, temperature 295K
Resolution 3.00 Å R-free 0.296
1ZOQ IRF3-CBP complex Deposited 2005-05-13 Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 196–386（191 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；298 K；0.2 M ammonium acetate, 0.15 M Mg acetate, 5% (v/v) PEG 4000, 50 mM Na HEPES, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.37 Å R-free 0.226
1ZOQ IRF3-CBP complex Deposited 2005-05-13 Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 196–386（191 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；298 K；0.2 M ammonium acetate, 0.15 M Mg acetate, 5% (v/v) PEG 4000, 50 mM Na HEPES, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.37 Å R-free 0.226
2O61 Crystal Structure of NFkB, IRF7, IRF3 bound to the interferon-b enhancer Deposited 2006-12-06 Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 1 Insufficient information Heteromer；Protein × 2 PDB declaration: tetrameric
Chain A 9–111（103 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；294 K；100 mM HEPES, pH 7.0, 15% (w/v) PEG 4000, VAPOR DIFFUSION, HANGING DROP, temperature 294K
Resolution 2.80 Å R-free 0.278
2O6G Crystal structure of IRF-3 bound to the interferon-b enhancer Deposited 2006-12-07 Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 1 Protein–DNA Homooligomer；Protein × 4 PDB declaration: hexameric
Chain E 1–123（123 aa） Fragment：DNA binding domain, residues 3-112
Chain F 1–123（123 aa） Fragment：DNA binding domain, residues 3-112
Chain G 1–123（123 aa） Fragment：DNA binding domain, residues 3-112
Chain H 1–123（123 aa） Fragment：DNA binding domain, residues 3-112
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8；294 K；100 mM Tris, 20% (w/v) PEG 6000, 500 mM NH4OAc, 100 mM NaCl, 5 mM MgCl2, 5% glycerol, pH 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 294K
Resolution 3.10 Å R-free 0.265
2PI0 Crystal Structure of IRF-3 bound to the PRDIII-I regulatory element of the human interferon-B enhancer Deposited 2007-04-12 Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 1 Protein–DNA Homooligomer；Protein × 4 PDB declaration: hexameric
Chain A 1–113（113 aa） Fragment：IRF-3 DNA Binding Domain
Chain B 1–113（113 aa） Fragment：IRF-3 DNA Binding Domain
Chain C 1–113（113 aa） Fragment：IRF-3 DNA Binding Domain
Chain D 1–113（113 aa） Fragment：IRF-3 DNA Binding Domain
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；12%PEG 400,200mM NaCl, pH 7., VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.31 Å R-free 0.264
3A77 The crystal structure of phosphorylated IRF-3 Deposited 2009-09-17 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 189–427（239 aa） Fragment：UNP residues 189-427
Non-standard monomer：Yes (specific site not provided by mmCIF) ACY ACETIC ACID × 1 MPD (4S)-2-METHYL-2,4-PENTANEDIOL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 5；277 K；10% MPD, 50mM sodium acetate pH 5.0, VAPOR DIFFUSION, SITTING DROP, temperature 277K
Resolution 1.80 Å R-free 0.221
3A77 The crystal structure of phosphorylated IRF-3 Deposited 2009-09-17 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 189–427（239 aa） Fragment：UNP residues 189-427
Non-standard monomer：Yes (specific site not provided by mmCIF) MPD (4S)-2-METHYL-2,4-PENTANEDIOL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 5；277 K；10% MPD, 50mM sodium acetate pH 5.0, VAPOR DIFFUSION, SITTING DROP, temperature 277K
Resolution 1.80 Å R-free 0.221
3A77 The crystal structure of phosphorylated IRF-3 Deposited 2009-09-17 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 3 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain C 189–427（239 aa） Fragment：UNP residues 189-427
Non-standard monomer：Yes (specific site not provided by mmCIF) ACY ACETIC ACID × 1 MPD (4S)-2-METHYL-2,4-PENTANEDIOL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 5；277 K；10% MPD, 50mM sodium acetate pH 5.0, VAPOR DIFFUSION, SITTING DROP, temperature 277K
Resolution 1.80 Å R-free 0.221
3A77 The crystal structure of phosphorylated IRF-3 Deposited 2009-09-17 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 4 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain D 189–427（239 aa） Fragment：UNP residues 189-427
Non-standard monomer：Yes (specific site not provided by mmCIF) MPD (4S)-2-METHYL-2,4-PENTANEDIOL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 5；277 K；10% MPD, 50mM sodium acetate pH 5.0, VAPOR DIFFUSION, SITTING DROP, temperature 277K
Resolution 1.80 Å R-free 0.221
5JEJ Phosphorylated STING in complex with IRF-3 CTD Deposited 2016-04-18 Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 5 PDB declaration: pentameric
Chain A 189–427（239 aa） Fragment：UNP residues 189-427
Chain B 189–427（239 aa） Fragment：UNP residues 189-427
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；277 K；0.1 M Bis-Tris, pH 5.5, 200 mM MgCl2, 20% PEG 3350
Resolution 2.00 Å R-free 0.237
5JEK Phosphorylated MAVS in complex with IRF-3 Deposited 2016-04-18 Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 189–427（239 aa） Fragment：UNP residues 189-427
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；277 K；0.1 M Bis-Tris pH 5.5, 80 mM MgCl2, 20% PEG 3350
Resolution 2.40 Å R-free 0.251
5JEK Phosphorylated MAVS in complex with IRF-3 Deposited 2016-04-18 Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 189–427（239 aa） Fragment：UNP residues 189-427
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；277 K；0.1 M Bis-Tris pH 5.5, 80 mM MgCl2, 20% PEG 3350
Resolution 2.40 Å R-free 0.251
5JEL Phosphorylated TRIF in complex with IRF-3 Deposited 2016-04-18 Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 189–427（239 aa） Fragment：UNP residues 189-427
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；277 K；0.1M NaAc pH 4.6, 2.0M NaCl
Resolution 1.60 Å R-free 0.187
5JEL Phosphorylated TRIF in complex with IRF-3 Deposited 2016-04-18 Different construct Different mutation/modification Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain A 189–427（239 aa） Fragment：UNP residues 189-427
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；277 K；0.1M NaAc pH 4.6, 2.0M NaCl
Resolution 1.60 Å R-free 0.187
5JEM Complex of IRF-3 with CBP Deposited 2016-04-18 Different construct Different mutation/modification Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain A 189–398（210 aa） Fragment：UNP residues 189-398
Chain B 189–398（210 aa） Fragment：UNP residues 189-398
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；277 K；0.1 M HEPES pH 7.5, 25% PEG 3350
Resolution 2.50 Å R-free 0.242
5JEM Complex of IRF-3 with CBP Deposited 2016-04-18 Different construct Different mutation/modification Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain E 189–398（210 aa） Fragment：UNP residues 189-398
Chain G 189–398（210 aa） Fragment：UNP residues 189-398
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；277 K；0.1 M HEPES pH 7.5, 25% PEG 3350
Resolution 2.50 Å R-free 0.242
5JEO Phosphorylated Rotavirus NSP1 in complex with IRF-3 Deposited 2016-04-18 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 189–427（239 aa） Fragment：UNP residues 189-427
Not recorded PO4 PHOSPHATE ION × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；277 K；0.1 M HEPES sodium pH7.5, 0.8 M NaH2PO4, 0.8 M KH2PO4
Resolution 1.72 Å R-free 0.183
5JEO Phosphorylated Rotavirus NSP1 in complex with IRF-3 Deposited 2016-04-18 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain A 189–427（239 aa） Fragment：UNP residues 189-427
Not recorded PO4 PHOSPHATE ION × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；277 K；0.1 M HEPES sodium pH7.5, 0.8 M NaH2PO4, 0.8 M KH2PO4
Resolution 1.72 Å R-free 0.183
5JER Structure of Rotavirus NSP1 bound to IRF-3 Deposited 2016-04-18 Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 189–427（239 aa） Fragment：UNP residues 189-427
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；277 K；0.1 M Bis-Tris pH 5.5, 200 mM MgCl2, 23% PEG 3350
Resolution 2.91 Å R-free 0.250
5JER Structure of Rotavirus NSP1 bound to IRF-3 Deposited 2016-04-18 Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain C 189–427（239 aa） Fragment：UNP residues 189-427
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；277 K；0.1 M Bis-Tris pH 5.5, 200 mM MgCl2, 23% PEG 3350
Resolution 2.91 Å R-free 0.250
5JER Structure of Rotavirus NSP1 bound to IRF-3 Deposited 2016-04-18 Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 3 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain E 189–427（239 aa） Fragment：UNP residues 189-427
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；277 K；0.1 M Bis-Tris pH 5.5, 200 mM MgCl2, 23% PEG 3350
Resolution 2.91 Å R-free 0.250
5JER Structure of Rotavirus NSP1 bound to IRF-3 Deposited 2016-04-18 Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 4 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain G 189–427（239 aa） Fragment：UNP residues 189-427
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；277 K；0.1 M Bis-Tris pH 5.5, 200 mM MgCl2, 23% PEG 3350
Resolution 2.91 Å R-free 0.250
5JER Structure of Rotavirus NSP1 bound to IRF-3 Deposited 2016-04-18 Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 5 Protein heterocomplex Heteromer；Protein × 8 PDB declaration: octameric
Chain A 189–427（239 aa） Fragment：UNP residues 189-427
Chain C 189–427（239 aa） Fragment：UNP residues 189-427
Chain E 189–427（239 aa） Fragment：UNP residues 189-427
Chain G 189–427（239 aa） Fragment：UNP residues 189-427
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；277 K；0.1 M Bis-Tris pH 5.5, 200 mM MgCl2, 23% PEG 3350
Resolution 2.91 Å R-free 0.250
6SIV Structure of HPV16 E6 oncoprotein in complex with mutant IRF3 LxxLL motif Deposited 2019-08-12 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Insufficient information Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 137–148（12 aa）
Mutation：;K84A,K240A,E360A,K363A,D364A,N2146E,M2147E,V2148R,K84A,K240A,E360A,K363A,D364A,N2146E,M2147E,V2148R,K84A,K240A,E360A,K363A,D364A,N2146E,M2147E,V2148R,K84A,K240A,E360A,K363A,D364A,N2146E,M2147E,V2148R ; ZN ZINC ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions EVAPORATION；298 K；PEG 1500 30%
Resolution 1.75 Å R-free 0.220
6SJA Structure of HPV16 E6 oncoprotein in complex with IRF3 LxxLL motif Deposited 2019-08-13 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Insufficient information Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 137–148（12 aa）
Mutation：E360A,K363A,D364A,K84A,K240A ZN ZINC ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions EVAPORATION；pH 6.8；298 K；PEG 1500 30%
Resolution 1.50 Å R-free 0.191

16 other PDB entries and 29 assemblies. Open the comparison page and filter oligomeric states

View Construct and Data Evidence
UniProt name IRF3_HUMAN
Isoform —
PDB entities 1
Chains and sequence ranges Author chain A； PDBConstruct 4–213； UniProt 189–398 Author chain B； PDBConstruct 4–213； UniProt 189–398

CREB-binding protein

Homo sapiens

UniProt Q92793

State in the Current Structure

Assembly Oligomeric State Construct Mutations and Modifications Ligands, Ions and Associated Components Method and Experimental Conditions Structure Quality
1 Protein heterocomplex Heteromer Protein × 4 PDB declaration: tetrameric（4） Consistent with protein copy count Chain C； UniProt 2065–2111 Chain D； UniProt 2065–2111 Not recorded Interferon regulatory factor 3 × 2 （Q14653） X-RAY DIFFRACTION X-ray crystallization conditions：VAPOR DIFFUSION, HANGING DROP；pH 5；277 K；0.1 M sodium acetate pH 5.0, 0.2 M MgCl2, 5% PEG 3350 Resolution 1.68 Å R-free 0.223

Other States of the Same Protein in the Database

Each row is a biological assembly of the same UniProt protein in another PDB entry. The “Difference from current entry” column identifies evidence-level differences; no tag means the currently parsed fields agree.

Other PDB Difference from Current Entry 7JFL Assembly / Oligomeric State Construct Mutations and Modifications Ligands, Ions and Non-polymers Method and Experimental Conditions Structure Quality
1JSP NMR Structure of CBP Bromodomain in complex with p53 peptide Deposited 2001-08-17 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 1081–1197（117 aa） Fragment：bromodomain
Not recorded No recorded non-water small molecule SOLUTION NMR
NMR measurement conditions pH 6.5；298 K；Pressure ambient
NMR measurement conditions pH 6.5；298 K；Pressure ambient
NMR measurement conditions pH 6.5；298 K；Pressure ambient
NMR measurement conditions pH 6.5；298 K；Pressure ambient
NMR sample composition 0.5mM CBP bromodomain U-15N; 0.5mM P53 peptide; 100mM phosphate buffer; pH 6.5 | 90% H2O/10% D2O
NMR sample composition 0.5mM CBP bromodomain U-15N,13C; 0.5mM P53 peptide;100mM phosphate buffer; pH 6.5 | 90% H2O/10% D2O
NMR sample composition 0.5mM CBP bromodomain U-15N,13C; 0.5mM P53 peptide;100mM phosphate buffer; pH 6.5 | 99.9%D2O
NMR sample composition 0.5mM CBP bromodomain U-15N,13C,75% 2H; 0.5mM P53 peptide;100mM phosphate buffer; pH 6.5 | 90% H2O/10% D2O
Resolution not provided
1LIQ Non-native Solution Structure of a fragment of the CH1 domain of CBP Deposited 2002-04-18 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 376–402（27 aa） Fragment：RESIDUES 1-27
Not recorded ZN ZINC ION × 1 SOLUTION NMR
NMR measurement conditions pH 6.5；275 K；Pressure ambient
NMR sample composition 0.4mM CBP(376-402), 0.6mM TCEP, 0.6mM ZnSO4, 95% H2O, 10% D2O | 95% H2O, 10% D2O
NMR sample composition 0.4mM CBP(376-402), 0.6mM TCEP, 0.6mM ZnSO4, 100% D2O | 100% D2O
Resolution not provided
1WO3 Solution structure of Minimal Mutant 1 (MM1): Multiple alanine mutant of non-native CHANCE domain Deposited 2004-08-12 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 376–400（25 aa） Fragment：CBP
Mutation：E1A, R3S, S6A, H9K, R11A, T12A, M13A, K14A, L17A, N18A, Q24A, A25K ZN ZINC ION × 1 SOLUTION NMR
NMR measurement conditions pH 6.9；275 K；Ionic strength (raw mmCIF value) 0；Pressure ambient
NMR sample composition 0.4mM MM1, 0.5mM TCEP, 1mM ZnSO4, 5% D2O | 95% H2O/5% D2O
NMR sample composition 0.4mM MM1, 0.5mM TCEP, 1mM ZnSO4, 100% D2O | 100% D2O
Resolution not provided
1WO4 Solution structure of Minimal Mutant 2 (MM2): Multiple alanine mutant of non-native CHANCE domain Deposited 2004-08-12 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 376–400（25 aa） Fragment：CBP
Mutation：E1A, R3S, S6A, P8S, H9K, R11A, T12A, M13A, K14A, L17A, N18A, Q24A, A25K ZN ZINC ION × 1 SOLUTION NMR
NMR measurement conditions pH 6.9；275 K；Ionic strength (raw mmCIF value) 0；Pressure ambient
NMR sample composition 0.4mM MM2, 0.5mM TCEP, 1mM ZnSO4, 5% D2O | 95% H2O/5% D2O
NMR sample composition 0.4mM MM2, 0.5mM TCEP, 1mM ZnSO4, 100% D2O | 100% D2O
Resolution not provided
1WO5 Solution structure of Designed Functional Finger 2 (DFF2): Designed mutant based on non-native CHANCE domain Deposited 2004-08-12 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 376–400（25 aa） Fragment：CBP
Mutation：E1R, R3I, S6F, P8K, H9V, R11A, T12A, M13A, K14A, L17A, N18A, Q24A, A25K ZN ZINC ION × 1 SOLUTION NMR
NMR measurement conditions pH 6.9；275 K；Ionic strength (raw mmCIF value) 0；Pressure ambient
NMR sample composition 0.3mM DFF2, 0.5mM TCEP, 1mM ZnSO4, 5% D2O | 95% H2O/5% D2O
Resolution not provided
1WO6 Solution structure of Designed Functional Finger 5 (DFF5): Designed mutant based on non-native CHANCE domain Deposited 2004-08-12 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 376–400（25 aa） Fragment：CBP
Mutation：E1A, R3Y, A4Y, S6I, H9K, R11A, T12A, M13A, K14A, L17A, N18A, M20T, Q24F, A25K ZN ZINC ION × 1 SOLUTION NMR
NMR measurement conditions pH 7.2；275 K；Ionic strength (raw mmCIF value) 0；Pressure ambient
NMR sample composition 0.3mM DFF5, 0.5mM TCEP, 1mM ZnSO4, 5% D2O | 95% H2O/5% D2O
Resolution not provided
1WO7 Solution structure of Designed Functional Finger 7 (DFF7): Designed mutant based on non-native CHANCE domain Deposited 2004-08-12 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 376–400（25 aa） Fragment：CBP
Mutation：E1F, R3S, A4T, S6Y, H9K, R11A, T12A, M13A, K14A, L17A, N18A, M20I, Q24Y, A25K ZN ZINC ION × 1 SOLUTION NMR
NMR measurement conditions pH 7；275 K；Ionic strength (raw mmCIF value) 0；Pressure ambient
NMR sample composition 0.25mM DFF7, 0.5mM TCEP, 1mM ZnSO4, 5% D2O | 95% H2O/5% D2O
Resolution not provided
1ZOQ IRF3-CBP complex Deposited 2005-05-13 Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain C 2065–2111（47 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；298 K；0.2 M ammonium acetate, 0.15 M Mg acetate, 5% (v/v) PEG 4000, 50 mM Na HEPES, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.37 Å R-free 0.226
1ZOQ IRF3-CBP complex Deposited 2005-05-13 Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain D 2065–2111（47 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；298 K；0.2 M ammonium acetate, 0.15 M Mg acetate, 5% (v/v) PEG 4000, 50 mM Na HEPES, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.37 Å R-free 0.226
2D82 Target Structure-Based Discovery of Small Molecules that Block Human p53 and CREB Binding Protein (CBP) Association Deposited 2005-12-01 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1081–1197（117 aa） Fragment：Bromodomain
Not recorded TTR 9-ACETYL-2,3,4,9-TETRAHYDRO-1H-CARBAZOL-1-ONE × 1 SOLUTION NMR
NMR measurement conditions pH 6.5；298 K；Pressure AMBIENT
NMR sample composition 0.5MM CBP BROMODOMAIN U-15N, 13C; 3.0MM CRB Ligand; 100MM PHOSPHATE BUFFER; PH 6.5 | 100% D2O
NMR sample composition 0.5MM CBP BROMODOMAIN U-15N, 13C, 75% 2H; 3.0MM CRB Ligand; 100MM PHOSPHATE BUFFER; PH 6.5 | 90% H2O/10% D2O
Resolution not provided
2KJE NMR structure of CBP TAZ2 and adenoviral E1A complex Deposited 2009-05-27 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 1763–1854（92 aa） Fragment：UNP residues 1763-1854
Not recorded ZN ZINC ION × 3 SOLUTION NMR
NMR measurement conditions pH 6.8；298 K；Ionic strength (raw mmCIF value) 0；Pressure ambient
NMR sample composition 1-1.5 mM [U-100% 13C; U-100% 15N] TRIS-1, 1-1.5 mM [U-100% 15N] TRIS-2, 100% D2O | 100% D2O
Resolution not provided
2KWF The structure of E-protein activation domain 1 bound to the KIX domain of CBP/p300 elucidates leukemia induction by E2A-PBX1 Deposited 2010-04-08 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 587–673（87 aa） Fragment：UNP residues 587-673, KIX domain
Not recorded No recorded non-water small molecule SOLUTION NMR
NMR measurement conditions pH 6；298 K；Ionic strength (raw mmCIF value) 0；Pressure ambient
NMR sample composition 1 mM DSS-1, 20 mM MES-2, 1 mM beta-mercaptoethanol-3, 90% H2O/10% D2O | 90% H2O/10% D2O
Resolution not provided
2L84 Solution NMR structures of CBP bromodomain with small molecule j28 Deposited 2011-01-03 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1081–1197（117 aa） Fragment：Bromo domain residues 1081-1197
Not recorded J28 5-[(E)-(2-amino-4-hydroxy-5-methylphenyl)diazenyl]-2,4-dimethylbenzenesulfonic acid × 1 SOLUTION NMR
NMR measurement conditions pH 6.5；298 K；Pressure ambient
NMR sample composition 0.5 mM [U-100% 13C; U-100% 15N] protein, 3 mM J28, 100 mM sodium phosphate, 3 mM [U-100% 2H] DTT, 90% H2O/10% D2O | 90% H2O/10% D2O
NMR sample composition 0.5 mM [U-100% 13C; U-100% 15N] protein, 3 mM J28, 100 mM sodium phosphate, 3 mM [U-100% 2H] DTT, 100% D2O | 100% D2O
Resolution not provided
2L85 Solution NMR structures of CBP bromodomain with small molecule of HBS Deposited 2011-01-04 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1081–1197（117 aa） Fragment：BROMO DOMAIN residues 1081-1197
Not recorded L85 4-[(E)-(4-hydroxyphenyl)diazenyl]benzenesulfonic acid × 1 SOLUTION NMR
NMR measurement conditions pH 6.5；298 K；Pressure ambient
NMR sample composition 0.5 mM [U-100% 13C; U-100% 15N] protein, 3 mM (E)-4-((4-hydroxyphenyl)diazenyl)benzenesulfonic acid, 100 mM sodium phosphate, 3 mM [U-100% 2H] DTT, 90% H2O/10% D2O | 90% H2O/10% D2O
NMR sample composition 0.5 mM [U-100% 13C; U-100% 15N] protein, 3 mM (E)-4-((4-hydroxyphenyl)diazenyl)benzenesulfonic acid, 100 mM sodium phosphate, 3 mM [U-100% 2H] DTT, 100% D2O | 100% D2O
Resolution not provided
2LXS Allosteric communication in the KIX domain proceeds through dynamic re-packing of the hydrophobic core Deposited 2012-08-31 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 587–673（87 aa） Fragment：UNP RESIDUES 587-673
Not recorded No recorded non-water small molecule SOLUTION NMR
NMR measurement conditions pH 5.8；300 K；Pressure ambient
NMR sample composition 1 mM [U-100% 13C; U-100% 15N] entity_1-1, 2 mM [U-100% 13C; U-100% 15N] entity_2-2, 25 mM sodium chloride-3, 50 mM potassium phosphate-4, 1 mM sodium azide-5, 90% H2O/10% D2O | 90% H2O/10% D2O
Resolution not provided
2LXT Allosteric communication in the KIX domain proceeds through dynamic re-packing of the hydrophobic core Deposited 2012-08-31 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric
Chain A 587–673（87 aa） Fragment：UNP RESIDUES 587-673
Not recorded No recorded non-water small molecule SOLUTION NMR
NMR measurement conditions pH 5.8；300 K；Pressure ambient
NMR sample composition 1 mM [U-100% 13C; U-100% 15N] entity_1-1, 2 mM entity_2-2, 2 mM [U-100% 13C; U-100% 15N] entity_3-3, 25 mM sodium chloride-4, 50 mM potassium phosphate-5, 1 mM sodium azide-6, 90% H2O/10% D2O | 90% H2O/10% D2O
Resolution not provided
2N1A Docked structure between SUMO1 and ZZ-domain from CBP Deposited 2015-03-26 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 1699–1751（53 aa）
Not recorded ZN ZINC ION × 2 SOLUTION NMR
NMR measurement conditions pH 6；298 K；Pressure ambient
NMR sample composition 20 mM MES, 93% H2O/7% D2O | 93% H2O/7% D2O
NMR sample composition 20 mM MES, 90% H2O, 10% D2O | 90% H2O/10% D2O
Resolution not provided
2RNY Complex Structures of CBP Bromodomain with H4 ack20 Peptide Deposited 2008-02-03 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 1081–1197（117 aa） Fragment：UNP residues 1081-1197
Not recorded No recorded non-water small molecule SOLUTION NMR
NMR measurement conditions pH 6.5；298 K；Ionic strength (raw mmCIF value) 0.1；Pressure ambient
NMR sample composition 0.5mM [U-100% 13C; U-100% 15N] sodium phosphate, 100% D2O | 100% D2O
Resolution not provided
3DWY Crystal Structure of the Bromodomain of Human CREBBP Deposited 2008-07-23 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1081–1197（117 aa） Fragment：Bromo domain: residues 1084-1197
Not recorded EDO 1,2-ETHANEDIOL × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.5；277 K；0.2M KSCN, 25% PEG3350, 5% EtGly, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K
Resolution 1.98 Å R-free 0.219
3DWY Crystal Structure of the Bromodomain of Human CREBBP Deposited 2008-07-23 Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 1081–1197（117 aa） Fragment：Bromo domain: residues 1084-1197
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.5；277 K；0.2M KSCN, 25% PEG3350, 5% EtGly, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K
Resolution 1.98 Å R-free 0.219
3P1C Crystal structure of the bromodomain of human CREBBP in complex with acetylated lysine Deposited 2010-09-30 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1081–1197（117 aa）
Not recorded ALY N(6)-ACETYLLYSINE × 1 SCN THIOCYANATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.5；277 K；0.2M KSCN 25% PEG3350 5% EtGly, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K
Resolution 1.82 Å R-free 0.218
3P1C Crystal structure of the bromodomain of human CREBBP in complex with acetylated lysine Deposited 2010-09-30 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 1081–1197（117 aa）
Not recorded ALY N(6)-ACETYLLYSINE × 1 K POTASSIUM ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.5；277 K；0.2M KSCN 25% PEG3350 5% EtGly, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K
Resolution 1.82 Å R-free 0.218
3P1D Crystal structure of the bromodomain of human CREBBP in complex with N-Methyl-2-pyrrolidone (NMP) Deposited 2010-09-30 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1081–1197（117 aa） Fragment：Bromo domain, UNP residues 1081-1197
Not recorded SCN THIOCYANATE ION × 1 MB3 1-methylpyrrolidin-2-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.5；277 K；0.2M KSCN 20% PEG3350 5% EtGly, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K
Resolution 1.86 Å R-free 0.218
3P1D Crystal structure of the bromodomain of human CREBBP in complex with N-Methyl-2-pyrrolidone (NMP) Deposited 2010-09-30 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 1081–1197（117 aa） Fragment：Bromo domain, UNP residues 1081-1197
Not recorded MB3 1-methylpyrrolidin-2-one × 1 K POTASSIUM ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.5；277 K；0.2M KSCN 20% PEG3350 5% EtGly, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K
Resolution 1.86 Å R-free 0.218
3P1E Crystal structure of the bromodomain of human CREBBP in complex with dimethyl sulfoxide (DMSO) Deposited 2010-09-30 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1081–1197（117 aa） Fragment：Bromo domain, UNP residues 1081-1197
Not recorded SCN THIOCYANATE ION × 1 DMS DIMETHYL SULFOXIDE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.5；277 K；0.2M KSCN 25% PEG3350 5% EtGly, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K
Resolution 1.80 Å R-free 0.236
3P1E Crystal structure of the bromodomain of human CREBBP in complex with dimethyl sulfoxide (DMSO) Deposited 2010-09-30 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 1081–1197（117 aa） Fragment：Bromo domain, UNP residues 1081-1197
Not recorded DMS DIMETHYL SULFOXIDE × 1 K POTASSIUM ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.5；277 K；0.2M KSCN 25% PEG3350 5% EtGly, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K
Resolution 1.80 Å R-free 0.236
3P1F Crystal structure of the bromodomain of human CREBBP in complex with a hydroquinazolin ligand Deposited 2010-09-30 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1081–1197（117 aa） Fragment：Bromo domain, UNP residues 1081-1197
Not recorded EDO 1,2-ETHANEDIOL × 3 K POTASSIUM ION × 1 3PF 3-methyl-3,4-dihydroquinazolin-2(1H)-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.5；277 K；0.15M KSCN 20% PEG3350 10% EtGly, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K
Resolution 1.63 Å R-free 0.218
3P1F Crystal structure of the bromodomain of human CREBBP in complex with a hydroquinazolin ligand Deposited 2010-09-30 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 1081–1197（117 aa） Fragment：Bromo domain, UNP residues 1081-1197
Not recorded EDO 1,2-ETHANEDIOL × 5 K POTASSIUM ION × 1 3PF 3-methyl-3,4-dihydroquinazolin-2(1H)-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.5；277 K；0.15M KSCN 20% PEG3350 10% EtGly, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K
Resolution 1.63 Å R-free 0.218
3SVH Crystal Structure of the bromdomain of human CREBBP in complex with a 3,5-dimethylisoxazol ligand Deposited 2011-07-12 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1081–1197（117 aa）
Not recorded KRG 3-(3,5-dimethyl-1,2-oxazol-4-yl)-5-ethoxybenzoic acid × 2 EDO 1,2-ETHANEDIOL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.5；277 K；0.25M KSCN, 10% PEG 3350, 5% EtGly, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K
Resolution 1.80 Å R-free 0.224
3SVH Crystal Structure of the bromdomain of human CREBBP in complex with a 3,5-dimethylisoxazol ligand Deposited 2011-07-12 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 1081–1197（117 aa）
Not recorded KRG 3-(3,5-dimethyl-1,2-oxazol-4-yl)-5-ethoxybenzoic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.5；277 K；0.25M KSCN, 10% PEG 3350, 5% EtGly, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K
Resolution 1.80 Å R-free 0.224
4A9K BROMODOMAIN OF HUMAN CREBBP WITH N-(4-hydroxyphenyl)acetamide Deposited 2011-11-26 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1081–1197（117 aa） Fragment：BROMODOMAIN, RESIDUES 1081-1197
Not recorded EDO 1,2-ETHANEDIOL × 2 TYL N-(4-HYDROXYPHENYL)ACETAMIDE (TYLENOL) × 1 SCN THIOCYANATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions 277 K；150 MM KSCN, 20% PEG 3350, 4 DEGREES CELSIUS.
Resolution 1.81 Å R-free 0.197
4A9K BROMODOMAIN OF HUMAN CREBBP WITH N-(4-hydroxyphenyl)acetamide Deposited 2011-11-26 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 1081–1197（117 aa） Fragment：BROMODOMAIN, RESIDUES 1081-1197
Not recorded TYL N-(4-HYDROXYPHENYL)ACETAMIDE (TYLENOL) × 1 K POTASSIUM ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions 277 K；150 MM KSCN, 20% PEG 3350, 4 DEGREES CELSIUS.
Resolution 1.81 Å R-free 0.197
4N3W Crystal Structure of the Bromodomain-PHD Finger Module of Human Transcriptional Co-Activator CBP in complex with Acetylated Histone 4 Peptide (H4K20ac). Deposited 2013-10-07 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 1080–1316（237 aa） Fragment：Bromodomain-PHD Finger Module, residues 1080-1316
Not recorded ZN ZINC ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；25% PEG 3,350, 0.2 M magnesium chloride, and 0.1 M HEPES, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 293K
Resolution 1.90 Å R-free 0.286
4N4F Crystal Structure of the Bromodomain-PHD Finger Module of Human Transcriptional Co-Activator CBP in complex with di-Acetylated Histone 4 Peptide (H412acK16ac). Deposited 2013-10-08 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 1080–1316（237 aa） Fragment：Bromodomain residues 1080-1316
Not recorded ZN ZINC ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；20% PEG MME 2,000, 0.2 M trimethylamine N-oxide, and 0.1 M Tris, pH 8.5, VAPOR DIFFUSION, SITTING DROP, temperature 293K
Resolution 1.83 Å R-free 0.241
4NR4 Crystal structure of the bromodomain of human CREBBP in complex with an isoxazolyl-benzimidazole ligand Deposited 2013-11-26 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1081–1197（117 aa） Fragment：UNP residues 1081-1197
Not recorded 2LK 1-(4-chlorobenzyl)-5-(3,5-dimethyl-1,2-oxazol-4-yl)-1H-benzimidazole × 1 EDO 1,2-ETHANEDIOL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8；277 K；0.1M MgCl, 0.1M Tris pH 8.0, 20% PEG 6K, 10% EtGly, VAPOR DIFFUSION, SITTING DROP, temperature 277K
Resolution 1.69 Å R-free 0.192
4NR4 Crystal structure of the bromodomain of human CREBBP in complex with an isoxazolyl-benzimidazole ligand Deposited 2013-11-26 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 1081–1197（117 aa） Fragment：UNP residues 1081-1197
Not recorded 2LK 1-(4-chlorobenzyl)-5-(3,5-dimethyl-1,2-oxazol-4-yl)-1H-benzimidazole × 2 EDO 1,2-ETHANEDIOL × 1 MG MAGNESIUM ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8；277 K；0.1M MgCl, 0.1M Tris pH 8.0, 20% PEG 6K, 10% EtGly, VAPOR DIFFUSION, SITTING DROP, temperature 277K
Resolution 1.69 Å R-free 0.192
4NR5 Crystal structure of the bromodomain of human CREBBP in complex with an isoxazolyl-benzimidazole ligand Deposited 2013-11-26 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1081–1197（117 aa） Fragment：UNP residues 1081-1197
Not recorded 2LL 5-(3,5-dimethyl-1,2-oxazol-4-yl)-1-[2-(morpholin-4-yl)ethyl]-2-(2-phenylethyl)-1H-benzimidazole × 1 NO3 NITRATE ION × 1 EDO 1,2-ETHANEDIOL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.5；277 K；0.20M NaNO3, 20.0% PEG 3350, 10.0% EtGly, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K
Resolution 1.66 Å R-free 0.226
4NR6 Crystal structure of the bromodomain of human CREBBP in complex with an oxazepin ligand Deposited 2013-11-26 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1081–1197（117 aa） Fragment：UNP residues 1081-1197
Not recorded 2LN 1-[7-(3,4-dimethoxyphenyl)-9-{[(3R)-1-methylpiperidin-3-yl]methoxy}-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]propan-1-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 6；277 K；0.10M MgCl2, 0.1M MES pH 6.0, 20.0% PEG 6K, 10.0% EtGly, VAPOR DIFFUSION, SITTING DROP, temperature 277K
Resolution 1.66 Å R-free 0.231
4NR7 Crystal structure of the bromodomain of human CREBBP in complex with an isoxazolyl-benzimidazole ligand Deposited 2013-11-26 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1081–1197（117 aa） Fragment：UNP residues 1081-1197
Not recorded EDO 1,2-ETHANEDIOL × 3 2LO 2-[2-(3-chloro-4-methoxyphenyl)ethyl]-5-(3,5-dimethyl-1,2-oxazol-4-yl)-1-[(2S)-2-(morpholin-4-yl)propyl]-1H-benzimidazole × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 6；277 K；0.20M NH4Cl, 0.1M MES pH 6.0, 20.0% PEG 6K, 10.0% EtGly, VAPOR DIFFUSION, SITTING DROP, temperature 277K
Resolution 1.20 Å R-free 0.144
4NYV Crystal Structure of the Bromodomain of human CREBBP in complex with a quinazolin-one ligand Deposited 2013-12-11 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1081–1197（117 aa） Fragment：UNP residues 1081-1197
Not recorded 15E 6-bromo-3-methyl-3,4-dihydroquinazolin-2(1H)-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.5；277 K；0.15M KSCN, 25% PEG_3350, 5% ethylene glycol, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K
Resolution 1.83 Å R-free 0.251
4NYV Crystal Structure of the Bromodomain of human CREBBP in complex with a quinazolin-one ligand Deposited 2013-12-11 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 1081–1197（117 aa） Fragment：UNP residues 1081-1197
Not recorded 15E 6-bromo-3-methyl-3,4-dihydroquinazolin-2(1H)-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.5；277 K；0.15M KSCN, 25% PEG_3350, 5% ethylene glycol, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K
Resolution 1.83 Å R-free 0.251
4NYV Crystal Structure of the Bromodomain of human CREBBP in complex with a quinazolin-one ligand Deposited 2013-12-11 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 3 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain C 1081–1197（117 aa） Fragment：UNP residues 1081-1197
Not recorded 15E 6-bromo-3-methyl-3,4-dihydroquinazolin-2(1H)-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.5；277 K；0.15M KSCN, 25% PEG_3350, 5% ethylene glycol, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K
Resolution 1.83 Å R-free 0.251
4NYV Crystal Structure of the Bromodomain of human CREBBP in complex with a quinazolin-one ligand Deposited 2013-12-11 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 4 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain D 1081–1197（117 aa） Fragment：UNP residues 1081-1197
Not recorded 15E 6-bromo-3-methyl-3,4-dihydroquinazolin-2(1H)-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.5；277 K；0.15M KSCN, 25% PEG_3350, 5% ethylene glycol, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K
Resolution 1.83 Å R-free 0.251
4NYW Crystal Structure of the Bromodomain of human CREBBP in complex with a dihydroquinoxalinone ligand Deposited 2013-12-11 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1081–1197（117 aa） Fragment：UNP residues 1081-1197
Not recorded SCN THIOCYANATE ION × 1 2O3 (3R)-N-[3-(3,4-dihydroquinolin-1(2H)-yl)propyl]-3-methyl-2-oxo-1,2,3,4-tetrahydroquinoxaline-5-carboxamide × 1 EDO 1,2-ETHANEDIOL × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.5；277 K；20% PEG 3350, 9% Ethylene Glycol, 0.18M KSCN, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K
Resolution 1.43 Å R-free 0.187
4NYX Crystal Structure of the Bromodomain of human CREBBP in complex with a dihydroquinoxalinone ligand Deposited 2013-12-11 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1081–1197（117 aa） Fragment：UNP residues 1081-1197
Not recorded 2O4 (3R)-N-[3-(7-methoxy-3,4-dihydroquinolin-1(2H)-yl)propyl]-3-methyl-2-oxo-1,2,3,4-tetrahydroquinoxaline-5-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8；277 K；0.05M CaCl2, 0.1M TRIS, 20.0% PEG 6K, 10.0% EtGly, pH 8.0, VAPOR DIFFUSION, SITTING DROP, temperature 277K
Resolution 1.10 Å R-free 0.135
4OUF Crystal Structure of CBP bromodomain Deposited 2014-02-17 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1082–1197（116 aa） Fragment：Bromo domain: residues 1082-1197
Not recorded PEG DI(HYDROXYETHYL)ETHER × 1 EDO 1,2-ETHANEDIOL × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；277 K；0.1 M HEPES-Na pH 7.0, 0.2M KSCN, 25% PEG3350 and 5% Ethylene Glycol, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 1.40 Å R-free 0.191
4OUF Crystal Structure of CBP bromodomain Deposited 2014-02-17 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 1082–1197（116 aa） Fragment：Bromo domain: residues 1082-1197
Not recorded EDO 1,2-ETHANEDIOL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；277 K；0.1 M HEPES-Na pH 7.0, 0.2M KSCN, 25% PEG3350 and 5% Ethylene Glycol, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 1.40 Å R-free 0.191
4TQN Crystal structure of the bromodomain of human CREBBP in complex with UL04 Deposited 2014-06-11 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: Monomeric
Chain A 1081–1197（117 aa） Fragment：Kinase domain, Residues 1081-1197
Not recorded UL4 3-[(5-acetyl-2-ethoxyphenyl)carbamoyl]benzoic acid × 1 EDO 1,2-ETHANEDIOL × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.5；277 K；0.1M MES pH 6.5, 0.1M MgCl2, 20% PEG 6000, 10% EtGly
Resolution 1.70 Å R-free 0.199
4TS8 Crystal structure of the bromodomain of human CREBBP in complex with XZ08 Deposited 2014-06-18 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: Monomeric
Chain A 1081–1197（117 aa） Fragment：Kinase domain, residues 1081-1197
Not recorded EDO 1,2-ETHANEDIOL × 2 XZ8 4-(1-acetyl-1H-indol-3-yl)-5-methyl-1,2-dihydro-3H-pyrazol-3-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.5；277 K；0.1M MES pH 6.5, 0.1M MgCl2, 20% PEG 3350 10% EtGly
Resolution 2.00 Å R-free 0.254
4WHU BROMO domain of CREB binding protein Deposited 2014-09-23 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1081–1197（117 aa） Fragment：UNP residues 1081-1197
Not recorded 3OT 2-methoxy-4-{1-[2-(morpholin-4-yl)ethyl]-2-(2-phenylethyl)-1H-benzimidazol-5-yl}cyclohepta-2,4,6-trien-1-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；277 K；obtained through screen with Hampton Research kits (HT and Index)
Resolution 2.11 Å R-free 0.261
4YK0 Crystal structure of the CBP bromodomain in complex with CPI098 Deposited 2015-03-03 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1045–1158（114 aa） Fragment：bromodomain
Not recorded 986 (4R)-4-methyl-1,3,4,5-tetrahydro-2H-1,5-benzodiazepin-2-one × 1 EDO 1,2-ETHANEDIOL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 6.5；277 K；0.1M Bis-Tris, pH 6.5 27% PEG3350 0.1M magnesium chloride
Resolution 1.65 Å R-free 0.269
4YK0 Crystal structure of the CBP bromodomain in complex with CPI098 Deposited 2015-03-03 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 1045–1158（114 aa） Fragment：bromodomain
Not recorded 986 (4R)-4-methyl-1,3,4,5-tetrahydro-2H-1,5-benzodiazepin-2-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 6.5；277 K；0.1M Bis-Tris, pH 6.5 27% PEG3350 0.1M magnesium chloride
Resolution 1.65 Å R-free 0.269
4YK0 Crystal structure of the CBP bromodomain in complex with CPI098 Deposited 2015-03-03 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 3 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain C 1045–1158（114 aa） Fragment：bromodomain
Not recorded 986 (4R)-4-methyl-1,3,4,5-tetrahydro-2H-1,5-benzodiazepin-2-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 6.5；277 K；0.1M Bis-Tris, pH 6.5 27% PEG3350 0.1M magnesium chloride
Resolution 1.65 Å R-free 0.269
4YK0 Crystal structure of the CBP bromodomain in complex with CPI098 Deposited 2015-03-03 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 4 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain D 1045–1158（114 aa） Fragment：bromodomain
Not recorded 986 (4R)-4-methyl-1,3,4,5-tetrahydro-2H-1,5-benzodiazepin-2-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 6.5；277 K；0.1M Bis-Tris, pH 6.5 27% PEG3350 0.1M magnesium chloride
Resolution 1.65 Å R-free 0.269
5CGP Selective pharmacological inhibition of the CREB binding protein bromodomain regulates inflammatory cytokines in macrophages and RGS4 in neurons Deposited 2015-07-09 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1081–1197（117 aa） Fragment：UNP residues 1081-1197
Not recorded 53W 5-(3,5-dimethyl-1,2-oxazol-4-yl)-2-[2-(4-methoxyphenyl)ethyl]-1-[2-(morpholin-4-yl)ethyl]-1H-benzimidazole × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；293 K；15-20% PEG 8000, 0.2M CaAcetate, 0.1 M cacodylate ph 6-7
Resolution 1.96 Å R-free 0.249
5DBM Crystal structure of the CBP bromodomain in complex with CPI703 Deposited 2015-08-21 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1082–1197（116 aa） Fragment：bromodomain (UNP residues 1082-1197)
Not recorded 58N (4R)-6-(1-tert-butyl-1H-pyrazol-4-yl)-4-methyl-1,3,4,5-tetrahydro-2H-1,5-benzodiazepin-2-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 9；277 K；0.1 M BICINE:NaOH pH 9.0, 20% (w/v) PEG 6000 (CPI703)
Resolution 1.86 Å R-free 0.220
5DBM Crystal structure of the CBP bromodomain in complex with CPI703 Deposited 2015-08-21 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 1082–1197（116 aa） Fragment：bromodomain (UNP residues 1082-1197)
Not recorded 58N (4R)-6-(1-tert-butyl-1H-pyrazol-4-yl)-4-methyl-1,3,4,5-tetrahydro-2H-1,5-benzodiazepin-2-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 9；277 K；0.1 M BICINE:NaOH pH 9.0, 20% (w/v) PEG 6000 (CPI703)
Resolution 1.86 Å R-free 0.220
5DBM Crystal structure of the CBP bromodomain in complex with CPI703 Deposited 2015-08-21 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 3 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain C 1082–1197（116 aa） Fragment：bromodomain (UNP residues 1082-1197)
Not recorded 58N (4R)-6-(1-tert-butyl-1H-pyrazol-4-yl)-4-methyl-1,3,4,5-tetrahydro-2H-1,5-benzodiazepin-2-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 9；277 K；0.1 M BICINE:NaOH pH 9.0, 20% (w/v) PEG 6000 (CPI703)
Resolution 1.86 Å R-free 0.220
5EIC Crystal structure of the bromodomain of human CREBBP in complex with AYC Deposited 2015-10-29 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1081–1197（117 aa）
Not recorded EDO 1,2-ETHANEDIOL × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；277 K；0.2M KSCN, 20% PEG3350, 10% EtGly, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K
Resolution 1.50 Å R-free 0.209
5EIC Crystal structure of the bromodomain of human CREBBP in complex with AYC Deposited 2015-10-29 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 1081–1197（117 aa）
Not recorded 5J5 2-[(chloroacetyl)amino]-5-[(E)-(4-sulfophenyl)diazenyl]benzenesulfonic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；277 K；0.2M KSCN, 20% PEG3350, 10% EtGly, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K
Resolution 1.50 Å R-free 0.209
5ENG Crystal structure of the bromodomain of human CREBBP in complex with UP39 Deposited 2015-11-09 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1081–1197（117 aa）
Not recorded 5QN methyl 2-[2-(3,5-dihydro-2~{H}-pyrazin-4-yl)ethoxy]-5-[(5-ethanoyl-2-ethoxy-phenyl)carbamoyl]benzoate × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；277 K；0.2M KSCN, 20% PEG3350, 10% EtGly, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K
Resolution 1.30 Å R-free 0.172
5EP7 Crystal structure of the bromodomain of human CREBBP in complex with UN32 Deposited 2015-11-11 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1081–1197（117 aa） Fragment：UNP residues 1081-1197
Not recorded 5QR 3-[(1-methyl-6-oxidanylidene-pyridin-3-yl)carbonylamino]benzoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；277 K；0.2M KSCN, 20% PEG3350, 10% EtGly, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K
Resolution 1.20 Å R-free 0.176
5GH9 Crystal structure of CBP Bromodomain with H3K56ac peptide Deposited 2016-06-19 Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 1081–1196（116 aa） Fragment：UNP residues 1081-1196
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；0.05 M Cadmium sulfate hydrate, 0.1 M HEPES, 1.0 M Sodium acetate trihydrate,
Resolution 1.45 Å R-free 0.176
5H85 Crystal structure of the bromodomain of human CREBBP in complex with UO37D Deposited 2015-12-23 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1081–1197（117 aa） Fragment：UNP residues 1081-1197
Not recorded 5XS methyl 3-(7~{H}-purin-6-ylcarbamoyl)benzoate × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；277 K；0.15M KSCN, 20% PEG 3350, 10% EtGly
Resolution 1.70 Å R-free 0.199
5I83 Crystal structure of the bromodomain of human CREBBP bound to the benzodiazepinone G02773986 Deposited 2016-02-18 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1082–1197（116 aa） Fragment：bromodomain (UNP residues 1082-1197)
Not recorded SCN THIOCYANATE ION × 1 68Y (4R)-4-methyl-7-[(1R)-1-phenylethoxy]-1,3,4,5-tetrahydro-2H-1,5-benzodiazepin-2-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；277.15 K；0.2 M potassium thiocyanate, 0.1 M Bis-Tris, pH 5.5, 5% v/v ethylene glycol, 23% PEG3350
Resolution 1.35 Å R-free 0.188
5I86 Crystal structure of the bromodomain of human CREBBP bound to the benzodiazepinone G02778174 Deposited 2016-02-18 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1082–1197（116 aa） Fragment：bromodomain (UNP residues 1082-1197)
Not recorded EDO 1,2-ETHANEDIOL × 1 SCN THIOCYANATE ION × 1 69A (4R)-N-benzyl-4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-1,5-benzodiazepine-6-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；277.15 K；0.2 M potassium thiocyanate, 0.1 M Bis-Tris, pH 5.5, 5% v/v ethylene glycol, 23% PEG3350
Resolution 1.05 Å R-free 0.161
5I86 Crystal structure of the bromodomain of human CREBBP bound to the benzodiazepinone G02778174 Deposited 2016-02-18 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 1082–1197（116 aa） Fragment：bromodomain (UNP residues 1082-1197)
Not recorded EDO 1,2-ETHANEDIOL × 1 69A (4R)-N-benzyl-4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-1,5-benzodiazepine-6-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；277.15 K；0.2 M potassium thiocyanate, 0.1 M Bis-Tris, pH 5.5, 5% v/v ethylene glycol, 23% PEG3350
Resolution 1.05 Å R-free 0.161
5I89 Crystal structure of the bromodomain of human CREBBP bound to the benzodiazepinone G02857790 Deposited 2016-02-18 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1082–1197（116 aa） Fragment：bromodomain (UNP residues 1082-1197)
Not recorded ACT ACETATE ION × 1 CA CALCIUM ION × 1 69B (4R)-6-(3-cyclopropyl-1-methyl-1H-indazol-5-yl)-4-methyl-1,3,4,5-tetrahydro-2H-1,5-benzodiazepin-2-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；277.15 K；0.2 M calcium acetate hydrate, and 20% w/v PEG3350
Resolution 1.07 Å R-free 0.137
5I8B CBP in complex with Cpd23 ((R)-6-(3-(benzyloxy)phenyl)-4-methyl-1,3,4,5-tetrahydro-2H-benzo[b][1,4]diazepin-2-one) Deposited 2016-02-18 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1081–1312（232 aa）
Not recorded ZN ZINC ION × 3 69F (4R)-6-[3-(benzyloxy)phenyl]-4-methyl-1,3,4,5-tetrahydro-2H-1,5-benzodiazepin-2-one × 1 B3P 2-[3-(2-HYDROXY-1,1-DIHYDROXYMETHYL-ETHYLAMINO)-PROPYLAMINO]-2-HYDROXYMETHYL-PROPANE-1,3-DIOL × 1 EDO 1,2-ETHANEDIOL × 5 NA SODIUM ION × 1 PEG DI(HYDROXYETHYL)ETHER × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；277 K；0.1 M Bis-Tris pH 8, 0.2 M sodium thiocyanate 19-23% PEG 3350
Resolution 1.52 Å R-free 0.200
5I8G CBP in complex with Cpd637 ((R)-4-methyl-6-(1-methyl-3-(1-methyl-1H-pyrazol-4-yl)-1H-indazol-5-yl)-1,3,4,5-tetrahydro-2H-benzo[b][1,4]diazepin-2-one) Deposited 2016-02-18 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1081–1312（232 aa）
Not recorded ZN ZINC ION × 3 69E (4R)-4-methyl-6-[1-methyl-3-(1-methyl-1H-pyrazol-4-yl)-1H-indazol-5-yl]-1,3,4,5-tetrahydro-2H-1,5-benzodiazepin-2-one × 1 B3P 2-[3-(2-HYDROXY-1,1-DIHYDROXYMETHYL-ETHYLAMINO)-PROPYLAMINO]-2-HYDROXYMETHYL-PROPANE-1,3-DIOL × 1 EDO 1,2-ETHANEDIOL × 5 NA SODIUM ION × 1 PEG DI(HYDROXYETHYL)ETHER × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8；277 K；containing 0.1 M Bis-Tris pH 8, 0.2 M sodium thiocyanate 19-23% PEG 3350
Resolution 1.41 Å R-free 0.210
5J0D Crystal structure of the bromodomain of human CREBBP in complex with a benzoxazepine compound Deposited 2016-03-28 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1081–1197（117 aa） Fragment：UNP residues 1081-1197
Not recorded 6F9 7-(3,5-dimethoxyphenyl)-N-[(3S)-1-methylpiperidin-3-yl]-4-propanoyl-2,3,4,5-tetrahydro-1,4-benzoxazepine-9-carboxamide × 1 EDO 1,2-ETHANEDIOL × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；pH 7.5；277 K；25% PEG3350, 0.2 M MgCl2, 0.1M BisTris pH 7.5
Resolution 1.05 Å R-free 0.197
5JEM Complex of IRF-3 with CBP Deposited 2016-04-18 Different construct Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain C 2065–2111（47 aa） Fragment：UNP residues 2065-2111
Chain D 2065–2111（47 aa） Fragment：UNP residues 2065-2111
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；277 K；0.1 M HEPES pH 7.5, 25% PEG 3350
Resolution 2.50 Å R-free 0.242
5JEM Complex of IRF-3 with CBP Deposited 2016-04-18 Different construct Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain F 2065–2111（47 aa） Fragment：UNP residues 2065-2111
Chain H 2065–2111（47 aa） Fragment：UNP residues 2065-2111
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；277 K；0.1 M HEPES pH 7.5, 25% PEG 3350
Resolution 2.50 Å R-free 0.242
5KTU Crystal structure of the bromodomain of human CREBBP bound to pyrazolopiperidine scaffold Deposited 2016-07-12 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1082–1197（116 aa） Fragment：bromodomain (UNP residues 1082-1197)
Not recorded 6XB 1-(3-phenylazanyl-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl)ethanone × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；277 K；0.2 M magnesium chloride, 0.1 M Bis-Tris pH 6.5, and 25% polyethylene glycol (PEG) 3350
Resolution 1.38 Å R-free 0.212
5KTU Crystal structure of the bromodomain of human CREBBP bound to pyrazolopiperidine scaffold Deposited 2016-07-12 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 1082–1197（116 aa） Fragment：bromodomain (UNP residues 1082-1197)
Not recorded DMS DIMETHYL SULFOXIDE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；277 K；0.2 M magnesium chloride, 0.1 M Bis-Tris pH 6.5, and 25% polyethylene glycol (PEG) 3350
Resolution 1.38 Å R-free 0.212
5KTW CREBBP bromodomain in complex with Cpd 44 (3-((5-acetyl-1-(cyclopropylmethyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)amino)-N-isopropylbenzamide) Deposited 2016-07-12 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1085–1196（112 aa） Fragment：bromodomain (UNP residues 1085-1196)
Not recorded 6XG 3-[[1-(cyclopropylmethyl)-5-ethanoyl-6,7-dihydro-4~{H}-pyrazolo[4,3-c]pyridin-3-yl]amino]-~{N}-propan-2-yl-benzamide × 1 EDO 1,2-ETHANEDIOL × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.5；277 K；0.2 M potassium thiocyanate, 0.1 M Bis-Tris pH 5.5, 5% v/v ethylene glycol, 23% PEG 3350
Resolution 1.09 Å R-free 0.176
5KTW CREBBP bromodomain in complex with Cpd 44 (3-((5-acetyl-1-(cyclopropylmethyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)amino)-N-isopropylbenzamide) Deposited 2016-07-12 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 1085–1196（112 aa） Fragment：bromodomain (UNP residues 1085-1196)
Not recorded 6XG 3-[[1-(cyclopropylmethyl)-5-ethanoyl-6,7-dihydro-4~{H}-pyrazolo[4,3-c]pyridin-3-yl]amino]-~{N}-propan-2-yl-benzamide × 1 EDO 1,2-ETHANEDIOL × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.5；277 K；0.2 M potassium thiocyanate, 0.1 M Bis-Tris pH 5.5, 5% v/v ethylene glycol, 23% PEG 3350
Resolution 1.09 Å R-free 0.176
5KTW CREBBP bromodomain in complex with Cpd 44 (3-((5-acetyl-1-(cyclopropylmethyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)amino)-N-isopropylbenzamide) Deposited 2016-07-12 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 3 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain C 1085–1196（112 aa） Fragment：bromodomain (UNP residues 1085-1196)
Not recorded 6XG 3-[[1-(cyclopropylmethyl)-5-ethanoyl-6,7-dihydro-4~{H}-pyrazolo[4,3-c]pyridin-3-yl]amino]-~{N}-propan-2-yl-benzamide × 1 EDO 1,2-ETHANEDIOL × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.5；277 K；0.2 M potassium thiocyanate, 0.1 M Bis-Tris pH 5.5, 5% v/v ethylene glycol, 23% PEG 3350
Resolution 1.09 Å R-free 0.176
5KTX CREBBP bromodomain in complex with Cpd59 ((S)-1-(3-((2-fluoro-4-(1-methyl-1H-pyrazol-4-yl)phenyl)amino)-1-(tetrahydrofuran-3-yl)-6,7-dihydro-1H-pyrazolo[4,3-c]pyridin-5(4H)-yl)ethanone) Deposited 2016-07-12 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1085–1196（112 aa） Fragment：bromodomain (UNP residues 1085-1196)
Not recorded 6XH 1-[3-[[2-fluoranyl-4-(1-methylpyrazol-4-yl)phenyl]amino]-1-[(3~{S})-oxolan-3-yl]-6,7-dihydro-4~{H}-pyrazolo[4,3-c]pyridin-5-yl]ethanone × 1 EDO 1,2-ETHANEDIOL × 2 DMS DIMETHYL SULFOXIDE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.5；287 K；0.2 M potassium thiocyanate, 0.1 M Bis-Tris pH 5.5, 5% v/v ethylene glycol, 23% PEG 3350
Resolution 1.27 Å R-free 0.172
5LPJ Crystal structure of the bromodomain of human CREBBP bound to the inhibitor XDM1 Deposited 2016-08-13 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1081–1197（117 aa） Fragment：bromodomain, UNP residues 1081-1197
Not recorded XDM ~{N}-[(3-chlorophenyl)methyl]-4-ethanoyl-3-ethyl-5-methyl-1~{H}-pyrrole-2-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions EVAPORATION；pH 6.5；277 K；LiSO4, PEG 3350
Resolution 1.65 Å R-free 0.196
5LPL Crystal structure of the bromodomain of human CREBBP bound to the inhibitor XDM3c Deposited 2016-08-13 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1081–1197（117 aa） Fragment：bromodomain, UNP residues 1081-1197
Not recorded 71X ~{N}-[(1~{R},2~{R})-7-chloranyl-2-oxidanyl-1,2,3,4-tetrahydronaphthalen-1-yl]-4-ethanoyl-3-ethyl-5-methyl-1~{H}-pyrrole-2-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions EVAPORATION；pH 7.5；277 K；NaCl, PEG 3350
Resolution 1.65 Å R-free 0.210
5MME Crystal structure of CREBBP bromodomain complexd with US46C Deposited 2016-12-09 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1081–1197（117 aa）
Not recorded 8Q6 dimethyl 5-[(5-ethanoyl-2-ethoxy-phenyl)amino]benzene-1,3-dicarboxylate × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；277 K；0.1 M Cacodylate, pH6.5, 0.2 M Calcium acetate, 18% PEG8000
Resolution 1.35 Å R-free 0.176
5MME Crystal structure of CREBBP bromodomain complexd with US46C Deposited 2016-12-09 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 1081–1197（117 aa）
Not recorded 8Q6 dimethyl 5-[(5-ethanoyl-2-ethoxy-phenyl)amino]benzene-1,3-dicarboxylate × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；277 K；0.1 M Cacodylate, pH6.5, 0.2 M Calcium acetate, 18% PEG8000
Resolution 1.35 Å R-free 0.176
5MMG Crystal structure of CREBBP bromodomain complexed with UT07C Deposited 2016-12-09 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1081–1197（117 aa） Fragment：bromodomain, UNP residues 1081-1197
Not recorded UT0 1-[4-ethoxy-3-[(1-methylsulfonylindol-6-yl)amino]phenyl]ethanone × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；277 K；0.15 M KSCN, 10% Ethylene Glycol, 20% PEG3350
Resolution 1.23 Å R-free 0.163
5MPK Crystal structure of CREBBP bromodomain complexed with DK19 Deposited 2016-12-16 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1081–1197（117 aa）
Not recorded 0BC ~{N}-(5-ethanoyl-2-ethoxy-phenyl)-3-(2~{H}-1,2,3,4-tetrazol-5-yl)-5-(1,3-thiazol-4-yl)benzamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；277 K；0.1 M HEPES-Na, pH7.5, 0.2 M MgCl2, 25% P3350
Resolution 1.90 Å R-free 0.239
5MPK Crystal structure of CREBBP bromodomain complexed with DK19 Deposited 2016-12-16 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 1081–1197（117 aa）
Not recorded 0BC ~{N}-(5-ethanoyl-2-ethoxy-phenyl)-3-(2~{H}-1,2,3,4-tetrazol-5-yl)-5-(1,3-thiazol-4-yl)benzamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；277 K；0.1 M HEPES-Na, pH7.5, 0.2 M MgCl2, 25% P3350
Resolution 1.90 Å R-free 0.239
5MPN Crystal structure of CREBBP bromodomain complexed with FA26 Deposited 2016-12-16 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1081–1197（117 aa） Fragment：bromodomain, UNP residues 1081-1197
Not recorded YE5 1-[4-ethoxy-3-[3-(2~{H}-1,2,3,4-tetrazol-5-yl)phenyl]phenyl]ethanone × 2 EDO 1,2-ETHANEDIOL × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.5；277 K；0.2 M MgCl2, 0.1 M Bis-Tris, pH6.5, 5% EG, 23% PEG3350
Resolution 1.23 Å R-free 0.167
5MPZ Crystal structure of CREBBP bromodomain complexed with CBP007 Deposited 2016-12-19 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1081–1197（117 aa） Fragment：bromodomain, UNP residues 1081-1197
Not recorded 4I8 methyl 2-oxidanylidene-3~{H}-1,3-benzoxazole-6-carboxylate × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；277 K；0.2 M MgCl2, 0.1 M Bis-Tris, pH 6.5, 5% v/v ethylene glycol, 23% PEG3350
Resolution 1.40 Å R-free 0.176
5MQE Crystal structure of CREBBP bromodomain complexed with CBP006 Deposited 2016-12-20 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1081–1197（117 aa） Fragment：bromodomain, UNP residues 1081-1197
Not recorded PKU 4-bromanyl-~{N}-methyl-1~{H}-pyrrole-2-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；277 K；0.2 M potassium thiocyanate, 0.1 M Bis-Tris, pH 5.5, 5% v/v ethylene glycol, 23% PEG3350
Resolution 1.65 Å R-free 0.225
5MQE Crystal structure of CREBBP bromodomain complexed with CBP006 Deposited 2016-12-20 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 1081–1197（117 aa） Fragment：bromodomain, UNP residues 1081-1197
Not recorded PKU 4-bromanyl-~{N}-methyl-1~{H}-pyrrole-2-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；277 K；0.2 M potassium thiocyanate, 0.1 M Bis-Tris, pH 5.5, 5% v/v ethylene glycol, 23% PEG3350
Resolution 1.65 Å R-free 0.225
5MQG Crystal structure of CREBBP bromodomain complexed with CBP015 Deposited 2016-12-20 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1081–1197（117 aa）
Not recorded F31 1-(4-azanyl-3-methoxy-phenyl)ethanone × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；277 K；0.2 M potassium thiocyanate, 0.1 M Bis-Tris, pH 5.5, 5% v/v ethylene glycol, 23% PEG3350
Resolution 1.35 Å R-free 0.191
5MQG Crystal structure of CREBBP bromodomain complexed with CBP015 Deposited 2016-12-20 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 1081–1197（117 aa）
Not recorded F31 1-(4-azanyl-3-methoxy-phenyl)ethanone × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；277 K；0.2 M potassium thiocyanate, 0.1 M Bis-Tris, pH 5.5, 5% v/v ethylene glycol, 23% PEG3350
Resolution 1.35 Å R-free 0.191
5MQK Crystal structure of CREBBP bromodomain complexed with CBP019 Deposited 2016-12-20 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1081–1197（117 aa） Fragment：bromodomain, UNP residues 1081-1197
Not recorded QPR 1-(1-methylindol-3-yl)ethanone × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；277 K；0.15 M KSCN, 20% PEG3350, 10% EG
Resolution 1.53 Å R-free 0.210
5MQK Crystal structure of CREBBP bromodomain complexed with CBP019 Deposited 2016-12-20 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 1081–1197（117 aa） Fragment：bromodomain, UNP residues 1081-1197
Not recorded QPR 1-(1-methylindol-3-yl)ethanone × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；277 K；0.15 M KSCN, 20% PEG3350, 10% EG
Resolution 1.53 Å R-free 0.210
5NLK Crystal structure of CREBBP bromodomain complexd with US13A Deposited 2017-04-04 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1081–1197（117 aa）
Not recorded 92E ~{N}-[3-acetamido-5-[(5-ethanoyl-2-ethoxy-phenyl)carbamoyl]phenyl]furan-2-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；277 K；0.1 M Buffer System 3, pH8.5, 37.50% v/v MPD_P1K_P3350, 0.09 M NPS
Resolution 1.80 Å R-free 0.216
5NRW Crystal structure of the human bromodomain of CREBBP bound to the inhibitor XDM4 Deposited 2017-04-25 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1081–1197（117 aa） Fragment：bromodomain, UNP residues 1081-1197
Not recorded 96N 4-ethanoyl-3-ethyl-5-methyl-~{N}-(naphthalen-1-ylmethyl)-1~{H}-pyrrole-2-carboxamide × 1 EDO 1,2-ETHANEDIOL × 4 X-RAY DIFFRACTION
X-ray crystallization conditions EVAPORATION；pH 6.5；277 K；LiSO4, PEG 3350, ethylene glycol
Resolution 1.70 Å R-free 0.260
5NU3 Crystal structure of the human bromodomain of CREBBP bound to the inhibitor XDM-CBP Deposited 2017-04-28 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1081–1197（117 aa） Fragment：bromodomain
Not recorded 99E ~{N}-[[2,8-bis(oxidanyl)naphthalen-1-yl]methyl]-4-ethanoyl-3-ethyl-5-methyl-1~{H}-pyrrole-2-carboxamide × 1 BU3 (R,R)-2,3-BUTANEDIOL × 4 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions EVAPORATION；pH 6.5；277 K；LiSO4, PEG 3350, ethylene glycol
Resolution 1.75 Å R-free 0.200
5OWK Crystal structure of CREBBP bromodomain complexed with DSPB2A002 Deposited 2017-09-01 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1081–1197（117 aa）
Not recorded 7MX ethyl 4-chloranyl-1-methyl-6-oxidanylidene-pyridine-3-carboxylate × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；277 K；0.1 M MES, pH6.5, 0.1 M MgCl2, 20% PEG6K, 10% EG
Resolution 1.25 Å R-free 0.176
5SVH Crystal structure of the KIX domain of CBP in complex with a MLL/c-Myb chimera Deposited 2016-08-06 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Insufficient information Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 587–673（87 aa） Fragment：UNP residues 587-673
Not recorded GOL GLYCEROL × 2 CL CHLORIDE ION × 7 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；295 K；0.1 M potassium sulfate 2.3M Ammonium sulphate
Resolution 2.05 Å R-free 0.242
5SVH Crystal structure of the KIX domain of CBP in complex with a MLL/c-Myb chimera Deposited 2016-08-06 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Insufficient information Heteromer；Protein × 12 PDB declaration: dodecameric
Chain A 587–673（87 aa） Fragment：UNP residues 587-673
Not recorded GOL GLYCEROL × 12 CL CHLORIDE ION × 42 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；295 K；0.1 M potassium sulfate 2.3M Ammonium sulphate
Resolution 2.05 Å R-free 0.242
5SVH Crystal structure of the KIX domain of CBP in complex with a MLL/c-Myb chimera Deposited 2016-08-06 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 3 Insufficient information Heteromer；Protein × 4 PDB declaration: tetrameric
Chain A 587–673（87 aa） Fragment：UNP residues 587-673
Not recorded GOL GLYCEROL × 4 CL CHLORIDE ION × 14 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；295 K；0.1 M potassium sulfate 2.3M Ammonium sulphate
Resolution 2.05 Å R-free 0.242
5TB6 Structure of bromodomain of CREBBP with a pyrazolo[4,3-c]pyridin fragment Deposited 2016-09-11 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1081–1197（117 aa）
Not recorded 77X 1-(3-phenyl-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl)propan-1-one × 1 EDO 1,2-ETHANEDIOL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.5；277 K；0.15M KSCN 15% PEG 3350 5% EtGly
Resolution 1.79 Å R-free 0.243
5W0E CREBBP bromodomain in complex with Cpd19 (3-(7-(difluoromethyl)-6-(1-methyl-1H-pyrazol-4-yl)-3,4-dihydroquinolin-1(2H)-yl)-N-methyl-1-(tetrahydro-2H-pyran-4-yl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide) Deposited 2017-05-30 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1082–1197（116 aa） Fragment：Bromodomain, UNP residues 1082-1197
Not recorded 9U4 3-[7-(difluoromethyl)-6-(1-methyl-1H-pyrazol-4-yl)-3,4-dihydroquinolin-1(2H)-yl]-N-methyl-1-(oxan-4-yl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；pH 6.5；277 K；0.2M MgCl2, 0.1M Bis-Tris pH6.5, 22% PEG3350
Resolution 1.41 Å R-free 0.260
5W0F CREBBP Bromodomain in complex with Cpd3 ((S)-1-(3-(6-(1-methyl-1H-pyrazol-4-yl)-3,4-dihydroquinolin-1(2H)-yl)-1-(tetrahydrofuran-3-yl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)ethan-1-one) Deposited 2017-05-30 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1082–1197（116 aa） Fragment：Bromodomain, UNP residues 1082-1197
Not recorded 9U7 1-{3-[6-(1-methyl-1H-pyrazol-4-yl)-3,4-dihydroquinolin-1(2H)-yl]-1-[(3S)-oxolan-3-yl]-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl}ethan-1-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；pH 6.5；277 K；0.2 M Li2SO4, 0.1M Bis-Tris pH 6.5, 19% PEG3350
Resolution 1.60 Å R-free 0.206
5W0L CREBBP Bromodomain in complex with Cpd10 (1-(3-(7-(difluoromethyl)-6-(1-methyl-1H-pyrazol-4-yl)-3,4-dihydroquinolin-1(2H)-yl)-1-(tetrahydro-2H-pyran-4-yl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)ethan-1-one) Deposited 2017-05-31 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1082–1197（116 aa） Fragment：Bromodomain, UNP residues 1082-1197
Not recorded 9UD 1-{3-[7-(difluoromethyl)-6-(1-methyl-1H-pyrazol-4-yl)-3,4-dihydroquinolin-1(2H)-yl]-1-(oxan-4-yl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl}ethan-1-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；pH 6.5；277 K；100 mM Bis-Tris pH 5.5, 200-300 mM KSCN, 21-25% PEG 3350
Resolution 1.55 Å R-free 0.229
5W0L CREBBP Bromodomain in complex with Cpd10 (1-(3-(7-(difluoromethyl)-6-(1-methyl-1H-pyrazol-4-yl)-3,4-dihydroquinolin-1(2H)-yl)-1-(tetrahydro-2H-pyran-4-yl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)ethan-1-one) Deposited 2017-05-31 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 1082–1197（116 aa） Fragment：Bromodomain, UNP residues 1082-1197
Not recorded 9UD 1-{3-[7-(difluoromethyl)-6-(1-methyl-1H-pyrazol-4-yl)-3,4-dihydroquinolin-1(2H)-yl]-1-(oxan-4-yl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl}ethan-1-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；pH 6.5；277 K；100 mM Bis-Tris pH 5.5, 200-300 mM KSCN, 21-25% PEG 3350
Resolution 1.55 Å R-free 0.229
5W0Q CREBBP Bromodomain in complex with Cpd17 (N,2,7-trimethyl-2,3-dihydro-4H-benzo[b][1,4]oxazine-4-carboxamide) Deposited 2017-05-31 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1082–1197（116 aa） Fragment：Bromodomain, UNP residues 1082-1197
Not recorded SO4 SULFATE ION × 3 9UG (2R)-N,2,7-trimethyl-2,3-dihydro-4H-1,4-benzoxazine-4-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；pH 6.5；277 K；0.1M Bis-Tris pH 6.5, 0.2M Li2SO4, 25% PEG3350
Resolution 1.70 Å R-free 0.213
5XXH Crystal Structure Analysis of the CBP Deposited 2017-07-04 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1081–1197（117 aa） Fragment：UNP RESIDUES 1081-1197
Not recorded E0D (3S)-1-[2-(3-ethanoylindol-1-yl)ethanoyl]piperidine-3-carboxylic acid × 1 EDO 1,2-ETHANEDIOL × 1 MG MAGNESIUM ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8.5；277 K；30% PEG 3350, 0.2M MgCl2, 0.1M Tris HCl, PH 8.5
Resolution 1.62 Å R-free 0.208
6ALB CREBBP bromodomain in complex with Cpd 30 (1-(3-(3-(1-methyl-1H-pyrazol-4-yl)isoquinolin-8-yl)-1-(tetrahydro-2H-pyran-4-yl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)ethan-1-one) Deposited 2017-08-07 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1081–1312（232 aa） Fragment：Bromodomain (UNP residue 1081-1312)
Not recorded ZN ZINC ION × 3 B3P 2-[3-(2-HYDROXY-1,1-DIHYDROXYMETHYL-ETHYLAMINO)-PROPYLAMINO]-2-HYDROXYMETHYL-PROPANE-1,3-DIOL × 1 BKJ 1-{3-[3-(1-methyl-1H-pyrazol-4-yl)isoquinolin-8-yl]-1-(oxan-4-yl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl}ethan-1-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；pH 6.5；277 K；0.2 M Li2SO4, 0.1M Bis-Tris pH 6.5, 19% PEG3350
Resolution 2.05 Å R-free 0.242
6ALC CREBBP bromodomain in complex with Cpd 4 (1-(1-(cyclopropylmethyl)-3-(1H-indol-4-yl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)ethan-1-one) Deposited 2017-08-07 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1085–1196（112 aa） Fragment：Bromodomain (UNP residues 1085-1196)
Not recorded DMS DIMETHYL SULFOXIDE × 1 EDO 1,2-ETHANEDIOL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；pH 6.5；277 K；0.2 M Li2SO4, 0.1M Bis-Tris pH 6.5, 19% PEG3350
Resolution 1.39 Å R-free 0.212
6ALC CREBBP bromodomain in complex with Cpd 4 (1-(1-(cyclopropylmethyl)-3-(1H-indol-4-yl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)ethan-1-one) Deposited 2017-08-07 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 1085–1196（112 aa） Fragment：Bromodomain (UNP residues 1085-1196)
Not recorded BKD 1-[1-(cyclopropylmethyl)-3-(1H-indol-4-yl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]ethan-1-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；pH 6.5；277 K；0.2 M Li2SO4, 0.1M Bis-Tris pH 6.5, 19% PEG3350
Resolution 1.39 Å R-free 0.212
6AXQ CREBBP bromodomain in complex with Cpd6 (methyl 1H-indole-3-carboxylate) Deposited 2017-09-07 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1085–1196（112 aa） Fragment：bromodomain (UNP residues 1085-1196)
Not recorded DMS DIMETHYL SULFOXIDE × 2 C2Y methyl 1H-indole-3-carboxylate × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；pH 8.2；289 K；3.545 M Formate, 100 mM Tris-HCl pH 8.2, 10% glycerol
Resolution 1.30 Å R-free 0.216
6AXQ CREBBP bromodomain in complex with Cpd6 (methyl 1H-indole-3-carboxylate) Deposited 2017-09-07 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 1085–1196（112 aa） Fragment：bromodomain (UNP residues 1085-1196)
Not recorded DMS DIMETHYL SULFOXIDE × 1 C2Y methyl 1H-indole-3-carboxylate × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；pH 8.2；289 K；3.545 M Formate, 100 mM Tris-HCl pH 8.2, 10% glycerol
Resolution 1.30 Å R-free 0.216
6AXQ CREBBP bromodomain in complex with Cpd6 (methyl 1H-indole-3-carboxylate) Deposited 2017-09-07 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 3 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain C 1085–1196（112 aa） Fragment：bromodomain (UNP residues 1085-1196)
Not recorded DMS DIMETHYL SULFOXIDE × 2 C2Y methyl 1H-indole-3-carboxylate × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；pH 8.2；289 K；3.545 M Formate, 100 mM Tris-HCl pH 8.2, 10% glycerol
Resolution 1.30 Å R-free 0.216
6AXQ CREBBP bromodomain in complex with Cpd6 (methyl 1H-indole-3-carboxylate) Deposited 2017-09-07 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 4 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain D 1085–1196（112 aa） Fragment：bromodomain (UNP residues 1085-1196)
Not recorded DMS DIMETHYL SULFOXIDE × 1 C2Y methyl 1H-indole-3-carboxylate × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；pH 8.2；289 K；3.545 M Formate, 100 mM Tris-HCl pH 8.2, 10% glycerol
Resolution 1.30 Å R-free 0.216
6AY3 CREBBP bromodomain in complex with Cpd16 (5-(7-(difluoromethyl)-6-(1-methyl-1H-pyrazol-4-yl)-3,4-dihydroquinolin-1(2H)-yl)-N-methyl-1H-indole-3-carboxamide) Deposited 2017-09-07 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1083–1197（115 aa） Fragment：Bromodomain (UNP residue 1083-1197)
Not recorded C3J 5-[7-(difluoromethyl)-6-(1-methyl-1H-pyrazol-4-yl)-3,4-dihydroquinolin-1(2H)-yl]-N-methyl-1H-indole-3-carboxamide × 1 EDO 1,2-ETHANEDIOL × 1 NA SODIUM ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；pH 6.5；277 K；0.2M MgCl2, 0.1M Bis-Tris pH6.5, 22% PEG3350
Resolution 1.39 Å R-free 0.237
6AY3 CREBBP bromodomain in complex with Cpd16 (5-(7-(difluoromethyl)-6-(1-methyl-1H-pyrazol-4-yl)-3,4-dihydroquinolin-1(2H)-yl)-N-methyl-1H-indole-3-carboxamide) Deposited 2017-09-07 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 1083–1197（115 aa） Fragment：Bromodomain (UNP residue 1083-1197)
Not recorded C3J 5-[7-(difluoromethyl)-6-(1-methyl-1H-pyrazol-4-yl)-3,4-dihydroquinolin-1(2H)-yl]-N-methyl-1H-indole-3-carboxamide × 1 EDO 1,2-ETHANEDIOL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；pH 6.5；277 K；0.2M MgCl2, 0.1M Bis-Tris pH6.5, 22% PEG3350
Resolution 1.39 Å R-free 0.237
6AY5 CREBBP bromodomain in complex with Cpd17 (5-(7-(difluoromethyl)-6-(1-methyl-1H-pyrazol-4-yl)-3,4-dihydroquinolin-1(2H)-yl)-3-methylbenzo[d]thiazol-2(3H)-one) Deposited 2017-09-07 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1083–1197（115 aa） Fragment：Bromodomain (UNP residue 1083-1197)
Not recorded C3V 5-[7-(difluoromethyl)-6-(1-methyl-1H-pyrazol-4-yl)-3,4-dihydroquinolin-1(2H)-yl]-3-methyl-1,3-benzothiazol-2(3H)-one × 1 SO4 SULFATE ION × 2 DMS DIMETHYL SULFOXIDE × 1 GOL GLYCEROL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；pH 6.5；277 K；0.2M MgCl2, 0.1M Bis-Tris pH6.5, 22% PEG3350
Resolution 1.44 Å R-free 0.184
6DMK A multiconformer ligand model of an isoxazolyl-benzimidazole ligand bound to the bromodomain of human CREBBP Deposited 2018-06-05 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1045–1157（113 aa）
Not recorded NO3 NITRATE ION × 1 2LL 5-(3,5-dimethyl-1,2-oxazol-4-yl)-1-[2-(morpholin-4-yl)ethyl]-2-(2-phenylethyl)-1H-benzimidazole × 1 EDO 1,2-ETHANEDIOL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.5；277 K；0.20M NaNO3, 20.0% PEG 3350, 10.0% EtGly, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K
Resolution 1.66 Å R-free 0.234
6ES7 Structure and dynamics conspire in the evolution of affinity between intrinsically disordered proteins Deposited 2017-10-19 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 2061–2109（49 aa）
Not recorded No recorded non-water small molecule SOLUTION NMR
NMR measurement conditions pH 6.5；298 K；Ionic strength (raw mmCIF value) na；Pressure 1
NMR sample composition 100 % 13C/15N CID, 100 % 13C/15N NCBD, 90% H2O/10% D2O | 90% H2O/10% D2O
Resolution not provided
6FQO Crystal structure of CREBBP bromodomain complexd with DT29 Deposited 2018-02-14 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1081–1197（117 aa）
Not recorded E2T ~{N}-[3-(2,5-dimethyl-3-oxidanylidene-1,2-oxazol-4-yl)-5-(5-ethanoyl-2-ethoxy-phenyl)phenyl]furan-2-carboxamide × 1 EDO 1,2-ETHANEDIOL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；277 K；0.15 M KSCN, 20% PEG3350, 10% EG
Resolution 1.35 Å R-free 0.194
6FQO Crystal structure of CREBBP bromodomain complexd with DT29 Deposited 2018-02-14 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 1081–1197（117 aa）
Not recorded E2T ~{N}-[3-(2,5-dimethyl-3-oxidanylidene-1,2-oxazol-4-yl)-5-(5-ethanoyl-2-ethoxy-phenyl)phenyl]furan-2-carboxamide × 1 EDO 1,2-ETHANEDIOL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；277 K；0.15 M KSCN, 20% PEG3350, 10% EG
Resolution 1.35 Å R-free 0.194
6FQT Crystal structure of CREBBP bromodomain complexd with DR46 Deposited 2018-02-14 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1081–1197（117 aa）
Not recorded AY2 ~{N}-[3-(5-ethanoyl-2-ethoxy-phenyl)-5-(1-methylpyrazol-3-yl)phenyl]furan-2-carboxamide × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；277 K；0.1 M Hepes, pH7.5, 0.2 M LiSO4, 25% PEG3350
Resolution 1.80 Å R-free 0.255
6FQU Crystal structure of CREBBP bromodomain complexd with DR09 Deposited 2018-02-14 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1081–1197（117 aa）
Not recorded E3B 1-[3-[3-[3,3-bis(fluoranyl)piperidin-1-yl]phenyl]-4-ethoxy-phenyl]ethanone × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；277 K；0.15 M KSCN, 20% PEG3350, 10% EG
Resolution 1.43 Å R-free 0.190
6FR0 Crystal structure of CREBBP bromodomain complexd with PB08 Deposited 2018-02-15 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1081–1197（117 aa）
Not recorded E3H ~{N}-[3-(5-ethanoyl-2-ethoxy-phenyl)-5-(2-ethyl-5-methyl-3-oxidanylidene-1,2-oxazol-4-yl)phenyl]furan-2-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；277 K；0.1 M Hepes, pH7.5, 0.2 M LiSO4, 25% PEG3350
Resolution 1.50 Å R-free 0.202
6FR0 Crystal structure of CREBBP bromodomain complexd with PB08 Deposited 2018-02-15 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 1081–1197（117 aa）
Not recorded E3H ~{N}-[3-(5-ethanoyl-2-ethoxy-phenyl)-5-(2-ethyl-5-methyl-3-oxidanylidene-1,2-oxazol-4-yl)phenyl]furan-2-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；277 K；0.1 M Hepes, pH7.5, 0.2 M LiSO4, 25% PEG3350
Resolution 1.50 Å R-free 0.202
6FRF Crystal structure of CREBBP bromodomain complexd with PA10 Deposited 2018-02-15 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1081–1197（117 aa）
Not recorded E3T ~{N}-[3-(3,5-dimethyl-1,2-oxazol-4-yl)-5-(5-ethanoyl-2-ethoxy-phenyl)phenyl]furan-2-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；277 K；0.1 M Sodium Citrate, pH 5.6, 1.3 M Ammonium Sulfate
Resolution 2.10 Å R-free 0.228
6FRF Crystal structure of CREBBP bromodomain complexd with PA10 Deposited 2018-02-15 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 1081–1197（117 aa）
Not recorded E3T ~{N}-[3-(3,5-dimethyl-1,2-oxazol-4-yl)-5-(5-ethanoyl-2-ethoxy-phenyl)phenyl]furan-2-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；277 K；0.1 M Sodium Citrate, pH 5.6, 1.3 M Ammonium Sulfate
Resolution 2.10 Å R-free 0.228
6FRF Crystal structure of CREBBP bromodomain complexd with PA10 Deposited 2018-02-15 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 3 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain C 1081–1197（117 aa）
Not recorded E3T ~{N}-[3-(3,5-dimethyl-1,2-oxazol-4-yl)-5-(5-ethanoyl-2-ethoxy-phenyl)phenyl]furan-2-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；277 K；0.1 M Sodium Citrate, pH 5.6, 1.3 M Ammonium Sulfate
Resolution 2.10 Å R-free 0.228
6FRF Crystal structure of CREBBP bromodomain complexd with PA10 Deposited 2018-02-15 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 4 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain D 1081–1197（117 aa）
Not recorded E3T ~{N}-[3-(3,5-dimethyl-1,2-oxazol-4-yl)-5-(5-ethanoyl-2-ethoxy-phenyl)phenyl]furan-2-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；277 K；0.1 M Sodium Citrate, pH 5.6, 1.3 M Ammonium Sulfate
Resolution 2.10 Å R-free 0.228
6QST Structure of CREBBP bromodomain with compound 2 bound Deposited 2019-02-22 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1081–1197（117 aa）
Not recorded JGK ~{N}-[3-(3-azanyl-5-methyl-1,2-oxazol-4-yl)-5-(5-ethanoyl-2-ethoxy-phenyl)phenyl]furan-2-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；277 K；0.1 M Bis-Tris propane pH 7.5, 0.02 M Sodium/potassium phosphate, 20% w/v PEG 3350
Resolution 2.10 Å R-free 0.219
6QST Structure of CREBBP bromodomain with compound 2 bound Deposited 2019-02-22 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 1081–1197（117 aa）
Not recorded JGK ~{N}-[3-(3-azanyl-5-methyl-1,2-oxazol-4-yl)-5-(5-ethanoyl-2-ethoxy-phenyl)phenyl]furan-2-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；277 K；0.1 M Bis-Tris propane pH 7.5, 0.02 M Sodium/potassium phosphate, 20% w/v PEG 3350
Resolution 2.10 Å R-free 0.219
6QST Structure of CREBBP bromodomain with compound 2 bound Deposited 2019-02-22 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 3 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain C 1081–1197（117 aa）
Not recorded JGK ~{N}-[3-(3-azanyl-5-methyl-1,2-oxazol-4-yl)-5-(5-ethanoyl-2-ethoxy-phenyl)phenyl]furan-2-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；277 K；0.1 M Bis-Tris propane pH 7.5, 0.02 M Sodium/potassium phosphate, 20% w/v PEG 3350
Resolution 2.10 Å R-free 0.219
6QST Structure of CREBBP bromodomain with compound 2 bound Deposited 2019-02-22 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 4 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain D 1081–1197（117 aa）
Not recorded JGK ~{N}-[3-(3-azanyl-5-methyl-1,2-oxazol-4-yl)-5-(5-ethanoyl-2-ethoxy-phenyl)phenyl]furan-2-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；277 K；0.1 M Bis-Tris propane pH 7.5, 0.02 M Sodium/potassium phosphate, 20% w/v PEG 3350
Resolution 2.10 Å R-free 0.219
6SQC Crystal structure of complex between nuclear coactivator binding domain of CBP and [1040-1086]ACTR containing alpha-methylated Leu1055 and Leu1076 Deposited 2019-09-03 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Insufficient information Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 2061–2112（52 aa）
Not recorded EDO 1,2-ETHANEDIOL × 1 ZN ZINC ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；298 K；20% PEG6000, 100 mM Tris pH 8 and 10 mM ZnCl2
Resolution 2.28 Å R-free 0.274
6SQE Crystal structure of CREBBP bromodomain complexed with KD341 Deposited 2019-09-03 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1081–1197（117 aa）
Not recorded LSZ ~{N}-[3-[(5-ethanoyl-2-ethoxy-phenyl)carbamoyl]-5-(1-methylpyrazol-3-yl)phenyl]-5-[(4-methylpiperazin-1-yl)methyl]furan-2-carboxamide × 1 EDO 1,2-ETHANEDIOL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；277.15 K；0.2M MgCl2, 25% PEG 3350, 0.1M BisTris pH 5.5
Resolution 1.51 Å R-free 0.191
6SQF Crystal structure of CREBBP bromodomain complexed with LB32A Deposited 2019-09-03 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1081–1197（117 aa）
Not recorded LTW ~{N}-[3-[[5-ethanoyl-2-[2-(2-oxa-6-azaspiro[3.3]heptan-6-yl)ethoxy]phenyl]carbamoyl]-5-(1-methylpyrazol-3-yl)phenyl]furan-2-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；277.15 K；0.1M MES pH 6.5, 12% PEG 20000
Resolution 2.01 Å R-free 0.215
6SQM Crystal structure of CREBBP bromodomain complexed with LA36 Deposited 2019-09-04 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1081–1197（117 aa）
Not recorded LU5 ~{N}-[3-acetamido-5-[(3-methylcinnolin-5-yl)carbamoyl]phenyl]furan-2-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；277.15 K；8% Ethylene glycol, 0.1M HEPES pH 7.5, 10% PEG 8000
Resolution 1.80 Å R-free 0.269
6SQM Crystal structure of CREBBP bromodomain complexed with LA36 Deposited 2019-09-04 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 1081–1197（117 aa）
Not recorded LU5 ~{N}-[3-acetamido-5-[(3-methylcinnolin-5-yl)carbamoyl]phenyl]furan-2-carboxamide × 1 EDO 1,2-ETHANEDIOL × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；277.15 K；8% Ethylene glycol, 0.1M HEPES pH 7.5, 10% PEG 8000
Resolution 1.80 Å R-free 0.269
6SQM Crystal structure of CREBBP bromodomain complexed with LA36 Deposited 2019-09-04 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 3 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain C 1081–1197（117 aa）
Not recorded LU5 ~{N}-[3-acetamido-5-[(3-methylcinnolin-5-yl)carbamoyl]phenyl]furan-2-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；277.15 K；8% Ethylene glycol, 0.1M HEPES pH 7.5, 10% PEG 8000
Resolution 1.80 Å R-free 0.269
6SXX Crystal structure of the bromodomain of human CREBBP in complex with ACA007 Deposited 2019-09-26 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1081–1197（117 aa）
Not recorded EDO 1,2-ETHANEDIOL × 2 LXQ (3~{R})-1-ethanoylpyrrolidine-3-carboxylic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；277 K；25% PEG3350, 0.2 M Potassium thiocyanate, 5% EtGly
Resolution 2.01 Å R-free 0.253
6SXX Crystal structure of the bromodomain of human CREBBP in complex with ACA007 Deposited 2019-09-26 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 1081–1197（117 aa）
Not recorded EDO 1,2-ETHANEDIOL × 1 LXQ (3~{R})-1-ethanoylpyrrolidine-3-carboxylic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；277 K；25% PEG3350, 0.2 M Potassium thiocyanate, 5% EtGly
Resolution 2.01 Å R-free 0.253
6YIJ Crystal structure of the CREBBP bromodomain in complex with a benzo-diazepine ligand Deposited 2020-04-01 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1081–1197（117 aa）
Not recorded OSN (4~{R})-6-[(~{E})-5-(7-methoxy-3,4-dihydro-2~{H}-quinolin-1-yl)pent-1-enyl]-4-methyl-1,3,4,5-tetrahydro-1,5-benzodiazepin-2-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8.3；277 K；20% ethylene glycol 21% PEG6K 0.1M tris pH 8.3 0.125M lithium chloride
Resolution 2.20 Å R-free 0.269
6YIJ Crystal structure of the CREBBP bromodomain in complex with a benzo-diazepine ligand Deposited 2020-04-01 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 1081–1197（117 aa）
Not recorded OSN (4~{R})-6-[(~{E})-5-(7-methoxy-3,4-dihydro-2~{H}-quinolin-1-yl)pent-1-enyl]-4-methyl-1,3,4,5-tetrahydro-1,5-benzodiazepin-2-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8.3；277 K；20% ethylene glycol 21% PEG6K 0.1M tris pH 8.3 0.125M lithium chloride
Resolution 2.20 Å R-free 0.269
6YIJ Crystal structure of the CREBBP bromodomain in complex with a benzo-diazepine ligand Deposited 2020-04-01 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 3 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain C 1081–1197（117 aa）
Not recorded OSN (4~{R})-6-[(~{E})-5-(7-methoxy-3,4-dihydro-2~{H}-quinolin-1-yl)pent-1-enyl]-4-methyl-1,3,4,5-tetrahydro-1,5-benzodiazepin-2-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8.3；277 K；20% ethylene glycol 21% PEG6K 0.1M tris pH 8.3 0.125M lithium chloride
Resolution 2.20 Å R-free 0.269
6YIJ Crystal structure of the CREBBP bromodomain in complex with a benzo-diazepine ligand Deposited 2020-04-01 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 4 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain D 1081–1197（117 aa）
Not recorded OSN (4~{R})-6-[(~{E})-5-(7-methoxy-3,4-dihydro-2~{H}-quinolin-1-yl)pent-1-enyl]-4-methyl-1,3,4,5-tetrahydro-1,5-benzodiazepin-2-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8.3；277 K；20% ethylene glycol 21% PEG6K 0.1M tris pH 8.3 0.125M lithium chloride
Resolution 2.20 Å R-free 0.269
6YIJ Crystal structure of the CREBBP bromodomain in complex with a benzo-diazepine ligand Deposited 2020-04-01 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 5 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain E 1081–1197（117 aa）
Not recorded OSN (4~{R})-6-[(~{E})-5-(7-methoxy-3,4-dihydro-2~{H}-quinolin-1-yl)pent-1-enyl]-4-methyl-1,3,4,5-tetrahydro-1,5-benzodiazepin-2-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8.3；277 K；20% ethylene glycol 21% PEG6K 0.1M tris pH 8.3 0.125M lithium chloride
Resolution 2.20 Å R-free 0.269
6YIJ Crystal structure of the CREBBP bromodomain in complex with a benzo-diazepine ligand Deposited 2020-04-01 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 6 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain F 1081–1197（117 aa）
Not recorded OSN (4~{R})-6-[(~{E})-5-(7-methoxy-3,4-dihydro-2~{H}-quinolin-1-yl)pent-1-enyl]-4-methyl-1,3,4,5-tetrahydro-1,5-benzodiazepin-2-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8.3；277 K；20% ethylene glycol 21% PEG6K 0.1M tris pH 8.3 0.125M lithium chloride
Resolution 2.20 Å R-free 0.269
6YIJ Crystal structure of the CREBBP bromodomain in complex with a benzo-diazepine ligand Deposited 2020-04-01 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 7 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain G 1081–1197（117 aa）
Not recorded OSN (4~{R})-6-[(~{E})-5-(7-methoxy-3,4-dihydro-2~{H}-quinolin-1-yl)pent-1-enyl]-4-methyl-1,3,4,5-tetrahydro-1,5-benzodiazepin-2-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8.3；277 K；20% ethylene glycol 21% PEG6K 0.1M tris pH 8.3 0.125M lithium chloride
Resolution 2.20 Å R-free 0.269
6YIK Crystal structure of the CREBBP bromodomain in complex with a tetrahydroquinoxaline ligand Deposited 2020-04-01 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1081–1197（117 aa）
Not recorded OSQ (3~{R})-~{N}-[3-(3,4-dihydro-2~{H}-quinolin-1-yl)-2,2-bis(fluoranyl)propyl]-3-methyl-2-oxidanylidene-3,4-dihydro-1~{H}-quinoxaline-5-carboxamide × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.5；277 K；21% PEG3350 15% ethylene glycol 0.25M sodium formate
Resolution 1.70 Å R-free 0.184
6YIK Crystal structure of the CREBBP bromodomain in complex with a tetrahydroquinoxaline ligand Deposited 2020-04-01 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 1081–1197（117 aa）
Not recorded OSQ (3~{R})-~{N}-[3-(3,4-dihydro-2~{H}-quinolin-1-yl)-2,2-bis(fluoranyl)propyl]-3-methyl-2-oxidanylidene-3,4-dihydro-1~{H}-quinoxaline-5-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.5；277 K；21% PEG3350 15% ethylene glycol 0.25M sodium formate
Resolution 1.70 Å R-free 0.184
6YIK Crystal structure of the CREBBP bromodomain in complex with a tetrahydroquinoxaline ligand Deposited 2020-04-01 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 3 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain C 1081–1197（117 aa）
Not recorded OSQ (3~{R})-~{N}-[3-(3,4-dihydro-2~{H}-quinolin-1-yl)-2,2-bis(fluoranyl)propyl]-3-methyl-2-oxidanylidene-3,4-dihydro-1~{H}-quinoxaline-5-carboxamide × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.5；277 K；21% PEG3350 15% ethylene glycol 0.25M sodium formate
Resolution 1.70 Å R-free 0.184
6YIL Crystal structure of the CREBBP bromodomain in complex with a tetrahydroquinoxaline ligand Deposited 2020-04-01 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1081–1197（117 aa）
Not recorded OSQ (3~{R})-~{N}-[3-(3,4-dihydro-2~{H}-quinolin-1-yl)-2,2-bis(fluoranyl)propyl]-3-methyl-2-oxidanylidene-3,4-dihydro-1~{H}-quinoxaline-5-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.5；277 K；20% PEG3350 10% ethylene glycol 0.2M sodium acetate
Resolution 1.22 Å R-free 0.151
6YIM Crystal structure of the CREBBP bromodomain in complex with a benzo-diazepine ligand Deposited 2020-04-01 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1081–1197（117 aa）
Not recorded OS8 (4~{R})-~{N}-[3-(7-methoxy-3,4-dihydro-2~{H}-quinolin-1-yl)propyl]-4-methyl-2-oxidanylidene-1,3,4,5-tetrahydro-1,5-benzodiazepine-6-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.5；277 K；20% PEG3350 10% ethylene glycol 0.2M sodium fluoride
Resolution 1.23 Å R-free 0.167
7CO1 Crystal structure of SMAD2 in complex with wild-type CBP Deposited 2020-08-03 Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric
Chain B 1951–1973（23 aa）
Chain D 1951–1973（23 aa）
Chain F 1951–1973（23 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8.2；293 K；1 M sodium phosphate monobasic monohydrate-potassium phosphate dibasic
Resolution 3.30 Å R-free 0.283
7EVJ Crystal structure of CBP bromodomain liganded with 9c Deposited 2021-05-21 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1081–1197（117 aa） Fragment：UNP RESIDUES 1081-1197
Not recorded JE9 3-acetyl-1-((3-(1-cyclopropyl-1H-pyrazol-4-yl)-2-fluoro-5-(hydroxymethyl)phenyl)carbamoyl)indolizin-7-yl dimethylcarbamate × 1 PO4 PHOSPHATE ION × 1 GOL GLYCEROL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 4.6；277 K；0.2 M NH4H2PO4, 20% PEG 3350, pH 4.6, and 20% Gly
Resolution 2.57 Å R-free 0.209
7JFM Crystal structure of mouse phosphorylated IRF-3 bound to CBP Deposited 2020-07-17 Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain C 2065–2111（47 aa）
Chain D 2065–2111（47 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；277 K；0.2 M ammonium citrate tribasic at pH 7.0, 12% PEG 3350
Resolution 2.23 Å R-free 0.252
7JUO CBP bromodomain complexed with YF2-23 Deposited 2020-08-20 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1082–1197（116 aa）
Not recorded YF2 N-{1-[1,1-di(pyridin-2-yl)ethyl]-6-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)-1H-indol-4-yl}ethanesulfonamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.4；277 K；0.2 M lithium citrate tribasic tetrahydrate, 17-19% PEG 3350, pH 8.4
Resolution 2.20 Å R-free 0.276
7JUO CBP bromodomain complexed with YF2-23 Deposited 2020-08-20 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain D 1082–1197（116 aa）
Not recorded YF2 N-{1-[1,1-di(pyridin-2-yl)ethyl]-6-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)-1H-indol-4-yl}ethanesulfonamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.4；277 K；0.2 M lithium citrate tribasic tetrahydrate, 17-19% PEG 3350, pH 8.4
Resolution 2.20 Å R-free 0.276
7JUO CBP bromodomain complexed with YF2-23 Deposited 2020-08-20 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 3 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain C 1082–1197（116 aa）
Not recorded YF2 N-{1-[1,1-di(pyridin-2-yl)ethyl]-6-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)-1H-indol-4-yl}ethanesulfonamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.4；277 K；0.2 M lithium citrate tribasic tetrahydrate, 17-19% PEG 3350, pH 8.4
Resolution 2.20 Å R-free 0.276
7JUO CBP bromodomain complexed with YF2-23 Deposited 2020-08-20 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 4 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 1082–1197（116 aa）
Not recorded YF2 N-{1-[1,1-di(pyridin-2-yl)ethyl]-6-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)-1H-indol-4-yl}ethanesulfonamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.4；277 K；0.2 M lithium citrate tribasic tetrahydrate, 17-19% PEG 3350, pH 8.4
Resolution 2.20 Å R-free 0.276
7JUO CBP bromodomain complexed with YF2-23 Deposited 2020-08-20 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 5 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain F 1082–1197（116 aa）
Not recorded YF2 N-{1-[1,1-di(pyridin-2-yl)ethyl]-6-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)-1H-indol-4-yl}ethanesulfonamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.4；277 K；0.2 M lithium citrate tribasic tetrahydrate, 17-19% PEG 3350, pH 8.4
Resolution 2.20 Å R-free 0.276
7JUO CBP bromodomain complexed with YF2-23 Deposited 2020-08-20 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 6 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain G 1082–1197（116 aa）
Not recorded YF2 N-{1-[1,1-di(pyridin-2-yl)ethyl]-6-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)-1H-indol-4-yl}ethanesulfonamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.4；277 K；0.2 M lithium citrate tribasic tetrahydrate, 17-19% PEG 3350, pH 8.4
Resolution 2.20 Å R-free 0.276
7JUO CBP bromodomain complexed with YF2-23 Deposited 2020-08-20 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 7 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain H 1082–1197（116 aa）
Not recorded YF2 N-{1-[1,1-di(pyridin-2-yl)ethyl]-6-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)-1H-indol-4-yl}ethanesulfonamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.4；277 K；0.2 M lithium citrate tribasic tetrahydrate, 17-19% PEG 3350, pH 8.4
Resolution 2.20 Å R-free 0.276
7JUO CBP bromodomain complexed with YF2-23 Deposited 2020-08-20 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 8 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain E 1082–1197（116 aa）
Not recorded YF2 N-{1-[1,1-di(pyridin-2-yl)ethyl]-6-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)-1H-indol-4-yl}ethanesulfonamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.4；277 K；0.2 M lithium citrate tribasic tetrahydrate, 17-19% PEG 3350, pH 8.4
Resolution 2.20 Å R-free 0.276
7RLE Crystal structure of PPAR gamma in complex with CREB-binding protein and agonist GW1929 Deposited 2021-07-23 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain B 57–80（24 aa） Fragment：Residues 57-80
Chain D 57–80（24 aa） Fragment：Residues 57-80
Not recorded EDK (2~{S})-3-[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]-2-[[2-(phenylcarbonyl)phenyl]amino]propanoic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 6.5；293.15 K；1M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate, pH 6.5
Resolution 2.50 Å R-free 0.275
7TB3 cryo-EM structure of MBP-KIX-apoferritin Deposited 2021-12-21 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Insufficient information Homooligomer；Protein × 24 PDB declaration: 24-meric
Chain A 549–630（82 aa）
Chain B 549–630（82 aa）
Chain C 549–630（82 aa）
Chain D 549–630（82 aa）
Chain E 549–630（82 aa）
Chain F 549–630（82 aa）
Chain G 549–630（82 aa）
Chain H 549–630（82 aa）
Chain I 549–630（82 aa）
Chain J 549–630（82 aa）
Chain K 549–630（82 aa）
Chain L 549–630（82 aa）
Chain M 549–630（82 aa）
Chain N 549–630（82 aa）
Chain O 549–630（82 aa）
Chain P 549–630（82 aa）
Chain Q 549–630（82 aa）
Chain R 549–630（82 aa）
Chain S 549–630（82 aa）
Chain T 549–630（82 aa）
Chain U 549–630（82 aa）
Chain V 549–630（82 aa）
Chain W 549–630（82 aa）
Chain X 549–630（82 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 8
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 2.57 Å
7TBH cryo-EM structure of MBP-KIX-apoferritin complex with peptide 7 Deposited 2021-12-22 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Insufficient information Heteromer；Protein × 48 PDB declaration: 48-meric
Chain A 549–630（82 aa）
Chain B 549–630（82 aa）
Chain C 549–630（82 aa）
Chain D 549–630（82 aa）
Chain E 549–630（82 aa）
Chain F 549–630（82 aa）
Chain G 549–630（82 aa）
Chain H 549–630（82 aa）
Chain I 549–630（82 aa）
Chain J 549–630（82 aa）
Chain K 549–630（82 aa）
Chain L 549–630（82 aa）
Chain M 549–630（82 aa）
Chain N 549–630（82 aa）
Chain O 549–630（82 aa）
Chain P 549–630（82 aa）
Chain Q 549–630（82 aa）
Chain R 549–630（82 aa）
Chain S 549–630（82 aa）
Chain T 549–630（82 aa）
Chain U 549–630（82 aa）
Chain V 549–630（82 aa）
Chain W 549–630（82 aa）
Chain X 549–630（82 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 8
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 2.30 Å
7WX2 CBP-BrD complexed with NEO2734 Deposited 2022-02-14 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1081–1197（117 aa） Fragment：bromodomain
Not recorded 7OW 1,3-dimethyl-5-[2-(oxan-4-yl)-3-[2-(trifluoromethyloxy)ethyl]benzimidazol-5-yl]pyridin-2-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions EVAPORATION；pH 8.5；289 K；PEG3350, NaNO3, ethylene glycol
Resolution 1.24 Å R-free 0.200
7XH6 Crystal structure of CBP bromodomain liganded with CCS1477 Deposited 2022-04-07 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1081–1197（117 aa） Fragment：UNP RESIDUES 1081-1197
Not recorded GOL GLYCEROL × 1 DMS DIMETHYL SULFOXIDE × 1 JHL (6S)-1-[3,4-bis(fluoranyl)phenyl]-6-[5-(3,5-dimethyl-1,2-oxazol-4-yl)-1-(4-methoxycyclohexyl)benzimidazol-2-yl]piperidin-2-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；277 K；0.1M HEPES pH 7.5, 2% v/v Tacsimate pH 7.0, 20% w/v Polyethylene glycol 3350
Resolution 1.75 Å R-free 0.227
7XH6 Crystal structure of CBP bromodomain liganded with CCS1477 Deposited 2022-04-07 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 1081–1197（117 aa） Fragment：UNP RESIDUES 1081-1197
Not recorded JHL (6S)-1-[3,4-bis(fluoranyl)phenyl]-6-[5-(3,5-dimethyl-1,2-oxazol-4-yl)-1-(4-methoxycyclohexyl)benzimidazol-2-yl]piperidin-2-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；277 K；0.1M HEPES pH 7.5, 2% v/v Tacsimate pH 7.0, 20% w/v Polyethylene glycol 3350
Resolution 1.75 Å R-free 0.227
7XHE Crystal structure of CBP bromodomain liganded with CCS151 Deposited 2022-04-08 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1081–1197（117 aa） Fragment：UNP RESIDUES 1081-1197
Not recorded JHF (6S)-6-[5-(3,5-dimethyl-1,2-oxazol-4-yl)-1-[(3R)-1-methylsulfonylpyrrolidin-3-yl]benzimidazol-2-yl]-1-(3-fluoranyl-4-methoxy-phenyl)piperidin-2-one × 1 EDO 1,2-ETHANEDIOL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；277 K；0.2M Sodium malonate pH 7.0, 20% w/v Polyethylene glycol 3350
Resolution 1.59 Å R-free 0.231
7XHE Crystal structure of CBP bromodomain liganded with CCS151 Deposited 2022-04-08 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 1081–1197（117 aa） Fragment：UNP RESIDUES 1081-1197
Not recorded JHF (6S)-6-[5-(3,5-dimethyl-1,2-oxazol-4-yl)-1-[(3R)-1-methylsulfonylpyrrolidin-3-yl]benzimidazol-2-yl]-1-(3-fluoranyl-4-methoxy-phenyl)piperidin-2-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；277 K；0.2M Sodium malonate pH 7.0, 20% w/v Polyethylene glycol 3350
Resolution 1.59 Å R-free 0.231
7XI0 Crystal structure of CBP bromodomain liganded with CCS150 Deposited 2022-04-11 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1081–1197（117 aa） Fragment：UNP RESIDUES 1081-1197
Not recorded EL0 (6S)-1-(3-chloranyl-4-methoxy-phenyl)-6-[5-(3,5-dimethyl-1,2-oxazol-4-yl)-1-[(3R)-1-methylsulfonylpyrrolidin-3-yl]benzimidazol-2-yl]piperidin-2-one × 1 GOL GLYCEROL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；277 K；0.2M NaAc, 20% w/v Polyethylene glycol, 3350 PH 7.3
Resolution 1.62 Å R-free 0.224
7XI0 Crystal structure of CBP bromodomain liganded with CCS150 Deposited 2022-04-11 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 1081–1197（117 aa） Fragment：UNP RESIDUES 1081-1197
Not recorded EL0 (6S)-1-(3-chloranyl-4-methoxy-phenyl)-6-[5-(3,5-dimethyl-1,2-oxazol-4-yl)-1-[(3R)-1-methylsulfonylpyrrolidin-3-yl]benzimidazol-2-yl]piperidin-2-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；277 K；0.2M NaAc, 20% w/v Polyethylene glycol, 3350 PH 7.3
Resolution 1.62 Å R-free 0.224
7XIJ Crystal structure of CBP bromodomain liganded with Y08175 Deposited 2022-04-13 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1043–1159（117 aa）
Not recorded EJ3 3-[(1-ethanoyl-5-methoxy-indol-3-yl)carbonylamino]-4-fluoranyl-5-(1-methylpyrazol-4-yl)benzoic acid × 1 DMS DIMETHYL SULFOXIDE × 1 GOL GLYCEROL × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；277 K；0.2M MgCl2 0.1M TrsHCl 30% PEG4000 PH7.5
Resolution 1.82 Å R-free 0.221
7XM7 Crystal Structure of the CBP in complex with the Y08188 Deposited 2022-04-25 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1081–1197（117 aa）
Not recorded GAY 3-ethanoyl-~{N}-[2-fluoranyl-3-(1-methylpyrazol-4-yl)phenyl]-7-methoxy-indolizine-1-carboxamide × 1 GOL GLYCEROL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；277 K；20% PEG3350 0.2M NH4NO3 PH6.2
Resolution 2.36 Å R-free 0.257
7XM7 Crystal Structure of the CBP in complex with the Y08188 Deposited 2022-04-25 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 1081–1197（117 aa）
Not recorded GAY 3-ethanoyl-~{N}-[2-fluoranyl-3-(1-methylpyrazol-4-yl)phenyl]-7-methoxy-indolizine-1-carboxamide × 1 NO3 NITRATE ION × 1 DMS DIMETHYL SULFOXIDE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；277 K；20% PEG3350 0.2M NH4NO3 PH6.2
Resolution 2.36 Å R-free 0.257
7XM7 Crystal Structure of the CBP in complex with the Y08188 Deposited 2022-04-25 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 3 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain C 1081–1197（117 aa）
Not recorded NO3 NITRATE ION × 1 PEG DI(HYDROXYETHYL)ETHER × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；277 K；20% PEG3350 0.2M NH4NO3 PH6.2
Resolution 2.36 Å R-free 0.257
7XM7 Crystal Structure of the CBP in complex with the Y08188 Deposited 2022-04-25 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 4 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain D 1081–1197（117 aa）
Not recorded EDO 1,2-ETHANEDIOL × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；277 K；20% PEG3350 0.2M NH4NO3 PH6.2
Resolution 2.36 Å R-free 0.257
7XNE Crystal structure of CBP bromodomain liganded with Y08284 Deposited 2022-04-28 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 1081–1197（117 aa） Fragment：UNP RESIDUES 1081-1197
Chain B 1081–1197（117 aa） Fragment：UNP RESIDUES 1081-1197
Not recorded GHF N-[3-(1-cyclopropylpyrazol-4-yl)-2-fluoranyl-5-[(1S)-1-oxidanylethyl]phenyl]-3-ethanoyl-7-methoxy-indolizine-1-carboxamide × 2 GOL GLYCEROL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；277 K；0.2 M Magnesium acetate tetrahydrate, 0.1 M Sodium cacodylate trihydrate pH 6.5, 20% w/v Polyethylene glycol 8,000
Resolution 2.17 Å R-free 0.259
7XNG Crystal structure of CBP bromodomain liganded with Y08092(31g) Deposited 2022-04-28 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 1081–1197（117 aa） Fragment：UNP RESIDUES 1081-1197
Chain B 1081–1197（117 aa） Fragment：UNP RESIDUES 1081-1197
Not recorded GI5 3-[(1-ethanoylindol-3-yl)carbonylamino]-5-[[(2S)-oxan-2-yl]oxymethyl]benzoic acid × 2 GOL GLYCEROL × 1 PEG DI(HYDROXYETHYL)ETHER × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；277 K；20% PEG3350 0.2M KSCN 0.1M HEPES PH8.5
Resolution 2.35 Å R-free 0.242
8FUP Bromodomain of CBP liganded with BMS-536924 and CCS-1477 Deposited 2023-01-18 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1082–1197（116 aa） Fragment：bromodomain
Not recorded N6I (3M)-4-{[(2S)-2-(3-chlorophenyl)-2-hydroxyethyl]amino}-3-[4-methyl-6-(morpholin-4-yl)-1H-benzimidazol-2-yl]pyridin-2(1H)-one × 1 JHL (6S)-1-[3,4-bis(fluoranyl)phenyl]-6-[5-(3,5-dimethyl-1,2-oxazol-4-yl)-1-(4-methoxycyclohexyl)benzimidazol-2-yl]piperidin-2-one × 1 EDO 1,2-ETHANEDIOL × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；292 K；0.2 M Ammonium sulfate, 30% w/v Polyethylene glycol 8000
Resolution 1.70 Å R-free 0.212
8FUP Bromodomain of CBP liganded with BMS-536924 and CCS-1477 Deposited 2023-01-18 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 1082–1197（116 aa） Fragment：bromodomain
Not recorded JHL (6S)-1-[3,4-bis(fluoranyl)phenyl]-6-[5-(3,5-dimethyl-1,2-oxazol-4-yl)-1-(4-methoxycyclohexyl)benzimidazol-2-yl]piperidin-2-one × 1 EDO 1,2-ETHANEDIOL × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；292 K；0.2 M Ammonium sulfate, 30% w/v Polyethylene glycol 8000
Resolution 1.70 Å R-free 0.212
8FV2 Bromodomain of CBP liganded with CCS-1477 Deposited 2023-01-18 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1082–1197（116 aa） Fragment：bromodomain
Not recorded PO4 PHOSPHATE ION × 3 JHL (6S)-1-[3,4-bis(fluoranyl)phenyl]-6-[5-(3,5-dimethyl-1,2-oxazol-4-yl)-1-(4-methoxycyclohexyl)benzimidazol-2-yl]piperidin-2-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8.2；293 K；0.056M Sodium phosphate monobasic monohydrate, 1.344M Potassium phosphate dibasic
Resolution 1.87 Å R-free 0.226
8FV2 Bromodomain of CBP liganded with CCS-1477 Deposited 2023-01-18 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 1082–1197（116 aa） Fragment：bromodomain
Not recorded PO4 PHOSPHATE ION × 2 JHL (6S)-1-[3,4-bis(fluoranyl)phenyl]-6-[5-(3,5-dimethyl-1,2-oxazol-4-yl)-1-(4-methoxycyclohexyl)benzimidazol-2-yl]piperidin-2-one × 2 EDO 1,2-ETHANEDIOL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8.2；293 K；0.056M Sodium phosphate monobasic monohydrate, 1.344M Potassium phosphate dibasic
Resolution 1.87 Å R-free 0.226
8FV2 Bromodomain of CBP liganded with CCS-1477 Deposited 2023-01-18 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 3 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain C 1082–1197（116 aa） Fragment：bromodomain
Not recorded JHL (6S)-1-[3,4-bis(fluoranyl)phenyl]-6-[5-(3,5-dimethyl-1,2-oxazol-4-yl)-1-(4-methoxycyclohexyl)benzimidazol-2-yl]piperidin-2-one × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8.2；293 K；0.056M Sodium phosphate monobasic monohydrate, 1.344M Potassium phosphate dibasic
Resolution 1.87 Å R-free 0.226
8FV2 Bromodomain of CBP liganded with CCS-1477 Deposited 2023-01-18 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 4 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain D 1082–1197（116 aa） Fragment：bromodomain
Not recorded JHL (6S)-1-[3,4-bis(fluoranyl)phenyl]-6-[5-(3,5-dimethyl-1,2-oxazol-4-yl)-1-(4-methoxycyclohexyl)benzimidazol-2-yl]piperidin-2-one × 1 EDO 1,2-ETHANEDIOL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8.2；293 K；0.056M Sodium phosphate monobasic monohydrate, 1.344M Potassium phosphate dibasic
Resolution 1.87 Å R-free 0.226
8FXA Bromodomain of CBP liganded with iCBP4 Deposited 2023-01-24 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1082–1197（116 aa） Fragment：bromodomain
Not recorded EDO 1,2-ETHANEDIOL × 3 YJY (6S)-1-[3,5-bis(trifluoromethyl)phenyl]-6-{(5M)-5-(3,5-dimethyl-1,2-oxazol-4-yl)-1-[(1s,4R)-4-methoxycyclohexyl]-1H-benzimidazol-2-yl}piperidin-2-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 5.5；291 K；0.2 M Magnesium chloride hexahydrate, 0.1 M BIS-TRIS pH 5.5, 25% w/v Polyethylene glycol 3350
Resolution 1.65 Å R-free 0.180
8FXA Bromodomain of CBP liganded with iCBP4 Deposited 2023-01-24 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 1082–1197（116 aa） Fragment：bromodomain
Not recorded EDO 1,2-ETHANEDIOL × 1 YJY (6S)-1-[3,5-bis(trifluoromethyl)phenyl]-6-{(5M)-5-(3,5-dimethyl-1,2-oxazol-4-yl)-1-[(1s,4R)-4-methoxycyclohexyl]-1H-benzimidazol-2-yl}piperidin-2-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 5.5；291 K；0.2 M Magnesium chloride hexahydrate, 0.1 M BIS-TRIS pH 5.5, 25% w/v Polyethylene glycol 3350
Resolution 1.65 Å R-free 0.180
8FXE Bromodomain of CBP liganded with iCBP6 Deposited 2023-01-24 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1081–1197（117 aa） Fragment：UNP residues 1081-1197
Not recorded YID (6S)-1-(3-tert-butylphenyl)-6-{(5P)-5-(3,5-dimethyl-1,2-oxazol-4-yl)-1-[(1s,4R)-4-methoxycyclohexyl]-1H-benzimidazol-2-yl}piperidin-2-one × 1 EDO 1,2-ETHANEDIOL × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8.5；292 K；0.2 M Sodium chloride, 0.1 M Tris pH 8.5, 25% w/v Polyethylene glycol 3350
Resolution 1.55 Å R-free 0.186
8FXN Bromodomain of CBP liganded with iCBP7 Deposited 2023-01-25 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1082–1197（116 aa） Fragment：bromodomain
Not recorded YN0 tert-butyl {(1R,4s)-4-[(5M)-2-[(2S)-1-(3-tert-butylphenyl)-6-oxopiperidin-2-yl]-5-(3,5-dimethyl-1,2-oxazol-4-yl)-1H-benzimidazol-1-yl]cyclohexyl}carbamate × 1 EDO 1,2-ETHANEDIOL × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；292 K；0.03M Sodium nitrate, 0.03 Sodium phosphate dibasic, 0.03M Ammonium sulfate, 0.1 M Imidazole, 0.1 M MES pH 6.5, 20% v/v PEG 500 MME; 10% w/v PEG 20000
Resolution 2.00 Å R-free 0.242
8FXO Bromodomain of CBP liganded with iCBP8 Deposited 2023-01-25 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1082–1197（116 aa） Fragment：bromodomain
Not recorded YN5 (6S)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-6-{(5M)-5-(3,5-dimethyl-1,2-oxazol-4-yl)-1-[(1s,4R)-4-methoxycyclohexyl]-1H-benzimidazol-2-yl}piperidin-2-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8.5；292 K；0.2 M Sodium acetate trihydrate, 0.1 M TRIS hydrochloride pH 8.5, 30% w/v Polyethylene glycol 4000
Resolution 1.74 Å R-free 0.205
8G6T Bromodomain of CBP liganded with inhibitor iCBP2 Deposited 2023-02-15 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1082–1197（116 aa）
Not recorded YRI (6S)-1-(3,4-dibromophenyl)-6-{(5M)-5-(3,5-dimethyl-1,2-oxazol-4-yl)-1-[(1s,4R)-4-methoxycyclohexyl]-1H-benzimidazol-2-yl}piperidin-2-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.5；292 K；0.01 M Nickel(II) chloride hexahydrate, 0.1 M Tris pH 8.5, 20% w/v Polyethylene glycol monomethyl ether 2,000
Resolution 1.75 Å R-free 0.222
8G6T Bromodomain of CBP liganded with inhibitor iCBP2 Deposited 2023-02-15 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 1082–1197（116 aa）
Not recorded YRI (6S)-1-(3,4-dibromophenyl)-6-{(5M)-5-(3,5-dimethyl-1,2-oxazol-4-yl)-1-[(1s,4R)-4-methoxycyclohexyl]-1H-benzimidazol-2-yl}piperidin-2-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.5；292 K；0.01 M Nickel(II) chloride hexahydrate, 0.1 M Tris pH 8.5, 20% w/v Polyethylene glycol monomethyl ether 2,000
Resolution 1.75 Å R-free 0.222
8G6T Bromodomain of CBP liganded with inhibitor iCBP2 Deposited 2023-02-15 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 3 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain C 1082–1197（116 aa）
Not recorded YRI (6S)-1-(3,4-dibromophenyl)-6-{(5M)-5-(3,5-dimethyl-1,2-oxazol-4-yl)-1-[(1s,4R)-4-methoxycyclohexyl]-1H-benzimidazol-2-yl}piperidin-2-one × 1 NI NICKEL (II) ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.5；292 K；0.01 M Nickel(II) chloride hexahydrate, 0.1 M Tris pH 8.5, 20% w/v Polyethylene glycol monomethyl ether 2,000
Resolution 1.75 Å R-free 0.222
8G6T Bromodomain of CBP liganded with inhibitor iCBP2 Deposited 2023-02-15 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 4 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain D 1082–1197（116 aa）
Not recorded YRI (6S)-1-(3,4-dibromophenyl)-6-{(5M)-5-(3,5-dimethyl-1,2-oxazol-4-yl)-1-[(1s,4R)-4-methoxycyclohexyl]-1H-benzimidazol-2-yl}piperidin-2-one × 1 NI NICKEL (II) ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.5；292 K；0.01 M Nickel(II) chloride hexahydrate, 0.1 M Tris pH 8.5, 20% w/v Polyethylene glycol monomethyl ether 2,000
Resolution 1.75 Å R-free 0.222
8GA2 Bromodomain of CBP liganded with inhibitor iCBP5 Deposited 2023-02-22 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1082–1197（116 aa） Fragment：Bromodomain, residues 1082-1197
Not recorded EDO 1,2-ETHANEDIOL × 1 YVK (6S)-6-{(5M)-5-(3,5-dimethyl-1,2-oxazol-4-yl)-1-[(1s,4R)-4-methoxycyclohexyl]-1H-benzimidazol-2-yl}-1-phenylpiperidin-2-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8.5；292 K；0.2 M Magnesium chloride hexahydrate; 0.1 M TRIS hydrochloride pH 8.5; 30% w/v Polyethylene glycol 4,000
Resolution 1.85 Å R-free 0.225
8GA2 Bromodomain of CBP liganded with inhibitor iCBP5 Deposited 2023-02-22 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain D 1082–1197（116 aa） Fragment：Bromodomain, residues 1082-1197
Not recorded YVK (6S)-6-{(5M)-5-(3,5-dimethyl-1,2-oxazol-4-yl)-1-[(1s,4R)-4-methoxycyclohexyl]-1H-benzimidazol-2-yl}-1-phenylpiperidin-2-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8.5；292 K；0.2 M Magnesium chloride hexahydrate; 0.1 M TRIS hydrochloride pH 8.5; 30% w/v Polyethylene glycol 4,000
Resolution 1.85 Å R-free 0.225
8GA2 Bromodomain of CBP liganded with inhibitor iCBP5 Deposited 2023-02-22 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 3 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain C 1082–1197（116 aa） Fragment：Bromodomain, residues 1082-1197
Not recorded YVK (6S)-6-{(5M)-5-(3,5-dimethyl-1,2-oxazol-4-yl)-1-[(1s,4R)-4-methoxycyclohexyl]-1H-benzimidazol-2-yl}-1-phenylpiperidin-2-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8.5；292 K；0.2 M Magnesium chloride hexahydrate; 0.1 M TRIS hydrochloride pH 8.5; 30% w/v Polyethylene glycol 4,000
Resolution 1.85 Å R-free 0.225
8GA2 Bromodomain of CBP liganded with inhibitor iCBP5 Deposited 2023-02-22 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 4 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 1082–1197（116 aa） Fragment：Bromodomain, residues 1082-1197
Not recorded YVK (6S)-6-{(5M)-5-(3,5-dimethyl-1,2-oxazol-4-yl)-1-[(1s,4R)-4-methoxycyclohexyl]-1H-benzimidazol-2-yl}-1-phenylpiperidin-2-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8.5；292 K；0.2 M Magnesium chloride hexahydrate; 0.1 M TRIS hydrochloride pH 8.5; 30% w/v Polyethylene glycol 4,000
Resolution 1.85 Å R-free 0.225
8HAL Cryo-EM structure of the CBP catalytic core bound to the H4K12acK16ac nucleosome, class 1 Deposited 2022-10-26 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein–DNA Heteromer；Protein × 9 PDB declaration: undecameric
Chain K 1084–1873（790 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7.2
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 4.40 Å
8HAM Cryo-EM structure of the CBP catalytic core bound to the H4K12acK16ac nucleosome, class 2 Deposited 2022-10-26 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein–DNA Heteromer；Protein × 9 PDB declaration: undecameric
Chain K 1084–1873（790 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7.2
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 4.50 Å
8HAN Cryo-EM structure of the CBP catalytic core bound to the H4K12acK16ac nucleosome, class 3 Deposited 2022-10-26 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein–DNA Heteromer；Protein × 9 PDB declaration: undecameric
Chain K 1084–1873（790 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7.2
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 4.20 Å
9GEJ Crystal structure of CREBBP bromodomain in complex with (2R,13S,E)-2-methyl-1,2,3,5,10,11,13,14,20,21,24,25-dodecahydro-19H,23H-16,18-etheno-9,13-methano-7,28-(metheno)[1,4]diazepino[2,3-k]pyrido[1,2-s][1,4]dioxa[7,19]diazacyclodocosine-4,8-dione Deposited 2024-08-07 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1081–1197（117 aa）
Not recorded A1IKJ 2R,13S,E)-2-methyl-1,2,3,5,10,11,13,14,20,21,24,25-dodecahydro-19H,23H-16,18-etheno-9,13-methano-7,28-(metheno)[1,4]diazepino[2,3-k]pyrido[1,2-s][1,4]dioxa[7,19]diazacyclodocosine-4,8-dione × 1 SO4 SULFATE ION × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；277 K；0.3 M LiSO4, 0.1 M Tris pH 8, PEG 3350
Resolution 1.84 Å R-free 0.220
9GEJ Crystal structure of CREBBP bromodomain in complex with (2R,13S,E)-2-methyl-1,2,3,5,10,11,13,14,20,21,24,25-dodecahydro-19H,23H-16,18-etheno-9,13-methano-7,28-(metheno)[1,4]diazepino[2,3-k]pyrido[1,2-s][1,4]dioxa[7,19]diazacyclodocosine-4,8-dione Deposited 2024-08-07 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 1081–1197（117 aa）
Not recorded A1IKJ 2R,13S,E)-2-methyl-1,2,3,5,10,11,13,14,20,21,24,25-dodecahydro-19H,23H-16,18-etheno-9,13-methano-7,28-(metheno)[1,4]diazepino[2,3-k]pyrido[1,2-s][1,4]dioxa[7,19]diazacyclodocosine-4,8-dione × 1 SO4 SULFATE ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；277 K；0.3 M LiSO4, 0.1 M Tris pH 8, PEG 3350
Resolution 1.84 Å R-free 0.220
9GEJ Crystal structure of CREBBP bromodomain in complex with (2R,13S,E)-2-methyl-1,2,3,5,10,11,13,14,20,21,24,25-dodecahydro-19H,23H-16,18-etheno-9,13-methano-7,28-(metheno)[1,4]diazepino[2,3-k]pyrido[1,2-s][1,4]dioxa[7,19]diazacyclodocosine-4,8-dione Deposited 2024-08-07 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 3 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain C 1081–1197（117 aa）
Not recorded SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；277 K；0.3 M LiSO4, 0.1 M Tris pH 8, PEG 3350
Resolution 1.84 Å R-free 0.220
9GEJ Crystal structure of CREBBP bromodomain in complex with (2R,13S,E)-2-methyl-1,2,3,5,10,11,13,14,20,21,24,25-dodecahydro-19H,23H-16,18-etheno-9,13-methano-7,28-(metheno)[1,4]diazepino[2,3-k]pyrido[1,2-s][1,4]dioxa[7,19]diazacyclodocosine-4,8-dione Deposited 2024-08-07 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 4 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain D 1081–1197（117 aa）
Not recorded A1IKJ 2R,13S,E)-2-methyl-1,2,3,5,10,11,13,14,20,21,24,25-dodecahydro-19H,23H-16,18-etheno-9,13-methano-7,28-(metheno)[1,4]diazepino[2,3-k]pyrido[1,2-s][1,4]dioxa[7,19]diazacyclodocosine-4,8-dione × 1 SO4 SULFATE ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；277 K；0.3 M LiSO4, 0.1 M Tris pH 8, PEG 3350
Resolution 1.84 Å R-free 0.220
9GEJ Crystal structure of CREBBP bromodomain in complex with (2R,13S,E)-2-methyl-1,2,3,5,10,11,13,14,20,21,24,25-dodecahydro-19H,23H-16,18-etheno-9,13-methano-7,28-(metheno)[1,4]diazepino[2,3-k]pyrido[1,2-s][1,4]dioxa[7,19]diazacyclodocosine-4,8-dione Deposited 2024-08-07 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 5 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain E 1081–1197（117 aa）
Not recorded A1IKJ 2R,13S,E)-2-methyl-1,2,3,5,10,11,13,14,20,21,24,25-dodecahydro-19H,23H-16,18-etheno-9,13-methano-7,28-(metheno)[1,4]diazepino[2,3-k]pyrido[1,2-s][1,4]dioxa[7,19]diazacyclodocosine-4,8-dione × 1 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；277 K；0.3 M LiSO4, 0.1 M Tris pH 8, PEG 3350
Resolution 1.84 Å R-free 0.220
9GEJ Crystal structure of CREBBP bromodomain in complex with (2R,13S,E)-2-methyl-1,2,3,5,10,11,13,14,20,21,24,25-dodecahydro-19H,23H-16,18-etheno-9,13-methano-7,28-(metheno)[1,4]diazepino[2,3-k]pyrido[1,2-s][1,4]dioxa[7,19]diazacyclodocosine-4,8-dione Deposited 2024-08-07 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 6 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain F 1081–1197（117 aa）
Not recorded A1IKJ 2R,13S,E)-2-methyl-1,2,3,5,10,11,13,14,20,21,24,25-dodecahydro-19H,23H-16,18-etheno-9,13-methano-7,28-(metheno)[1,4]diazepino[2,3-k]pyrido[1,2-s][1,4]dioxa[7,19]diazacyclodocosine-4,8-dione × 1 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；277 K；0.3 M LiSO4, 0.1 M Tris pH 8, PEG 3350
Resolution 1.84 Å R-free 0.220
9GEJ Crystal structure of CREBBP bromodomain in complex with (2R,13S,E)-2-methyl-1,2,3,5,10,11,13,14,20,21,24,25-dodecahydro-19H,23H-16,18-etheno-9,13-methano-7,28-(metheno)[1,4]diazepino[2,3-k]pyrido[1,2-s][1,4]dioxa[7,19]diazacyclodocosine-4,8-dione Deposited 2024-08-07 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 7 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain G 1081–1197（117 aa）
Not recorded A1IKJ 2R,13S,E)-2-methyl-1,2,3,5,10,11,13,14,20,21,24,25-dodecahydro-19H,23H-16,18-etheno-9,13-methano-7,28-(metheno)[1,4]diazepino[2,3-k]pyrido[1,2-s][1,4]dioxa[7,19]diazacyclodocosine-4,8-dione × 2 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；277 K；0.3 M LiSO4, 0.1 M Tris pH 8, PEG 3350
Resolution 1.84 Å R-free 0.220
9GET Crystal structure of CREBBP bromodomain in complex with (R,E)-6-(5-(7-methoxy-3,4-dihydroquinolin-1(2H)-yl)pent-1-en-1-yl)-4-methyl-8-(morpholine-4-carbonyl)-1,3,4,5-tetrahydro-2H-benzo[b][1,4]diazepin-2-one Deposited 2024-08-07 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1081–1197（117 aa）
Not recorded A1IKM (4~{R})-6-[(~{E})-5-(7-methoxy-3,4-dihydro-2~{H}-quinolin-1-yl)pent-1-enyl]-4-methyl-8-morpholin-4-ylcarbonyl-1,3,4,5-tetrahydro-1,5-benzodiazepin-2-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；277 K；0.1 M HEPES pH 7.5, 25% PEG 3,350
Resolution 1.29 Å R-free 0.167
9GEU Crystal structure of CREBBP bromodomain in complex with (R,E)-2-methyl-1,2,3,5,10,11,17,18,21,22-decahydro-4H,16H,20H-13,15-etheno-7,25-(metheno)[1,4]diazepino[2,3-h]pyrido[1,2-p][1]oxa[4,16]diazacyclononadecine-4,8(9H)-dione Deposited 2024-08-07 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1081–1197（117 aa）
Not recorded BU3 (R,R)-2,3-BUTANEDIOL × 2 A1IKL (R,E)-2-methyl-1,2,3,5,10,11,17,18,21,22-decahydro-4H,16H,20H-13,15-etheno-7,25-(metheno)[1,4]diazepino[2,3-h]pyrido[1,2-p][1]oxa[4,16]diazacyclononadecine-4,8(9H)-dione × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 3.5；277 K；0.1M citric acid, PEG 3350
Resolution 1.56 Å R-free 0.197
9GEU Crystal structure of CREBBP bromodomain in complex with (R,E)-2-methyl-1,2,3,5,10,11,17,18,21,22-decahydro-4H,16H,20H-13,15-etheno-7,25-(metheno)[1,4]diazepino[2,3-h]pyrido[1,2-p][1]oxa[4,16]diazacyclononadecine-4,8(9H)-dione Deposited 2024-08-07 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 1081–1197（117 aa）
Not recorded BU3 (R,R)-2,3-BUTANEDIOL × 1 A1IKL (R,E)-2-methyl-1,2,3,5,10,11,17,18,21,22-decahydro-4H,16H,20H-13,15-etheno-7,25-(metheno)[1,4]diazepino[2,3-h]pyrido[1,2-p][1]oxa[4,16]diazacyclononadecine-4,8(9H)-dione × 1 CIT CITRIC ACID × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 3.5；277 K；0.1M citric acid, PEG 3350
Resolution 1.56 Å R-free 0.197
9GEW Crystal structure of CREBBP bromodomain in complex with (R,E)-6-(5-(6-methoxy-2,3-dihydro-4H-benzo[b][1,4]oxazin-4-yl)pent-1-en-1-yl)-4-methyl-1,3,4,5-tetrahydro-2H-benzo[b][1,4]diazepin-2-one Deposited 2024-08-07 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1081–1197（117 aa）
Not recorded A1IKI (4~{R})-6-[(~{E})-5-(6-methoxy-2,3-dihydro-1,4-benzoxazin-4-yl)pent-1-enyl]-4-methyl-1,3,4,5-tetrahydro-1,5-benzodiazepin-2-one × 1 BU3 (R,R)-2,3-BUTANEDIOL × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；277 K；5% Tacsimate pH 7, 0.1 M Hepes pH 7, 10% PEG monomethyl ether 5000
Resolution 1.47 Å R-free 0.198
9GEY Crystal structure of CREBBP bromodomain in complex with (R,E)-2-methyl-1,2,3,5,9,10,11,12,18,19,22,23-dodecahydro-17H,21H-14,16-etheno-7,26-(metheno)[1,4]diazepino[2,3-l]pyrido[2,1-d][1]oxa[5,17]diazacycloicosine-4,8-dione Deposited 2024-08-07 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1081–1197（117 aa）
Not recorded A1IKK (R,E)-2-methyl-1,2,3,5,9,10,11,12,18,19,22,23-dodecahydro-17H,21H-14,16-etheno-7,26-(metheno)[1,4]diazepino[2,3-l]pyrido[2,1-d][1]oxa[5,17]diazacycloicosine-4,8-dione × 1 EDO 1,2-ETHANEDIOL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；277 K；0.2 M Ammonium acetate, 0.1 M Tris pH 8.5, 25% PEG 3,350
Resolution 1.56 Å R-free 0.211
9GEY Crystal structure of CREBBP bromodomain in complex with (R,E)-2-methyl-1,2,3,5,9,10,11,12,18,19,22,23-dodecahydro-17H,21H-14,16-etheno-7,26-(metheno)[1,4]diazepino[2,3-l]pyrido[2,1-d][1]oxa[5,17]diazacycloicosine-4,8-dione Deposited 2024-08-07 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 1081–1197（117 aa）
Not recorded A1IKK (R,E)-2-methyl-1,2,3,5,9,10,11,12,18,19,22,23-dodecahydro-17H,21H-14,16-etheno-7,26-(metheno)[1,4]diazepino[2,3-l]pyrido[2,1-d][1]oxa[5,17]diazacycloicosine-4,8-dione × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；277 K；0.2 M Ammonium acetate, 0.1 M Tris pH 8.5, 25% PEG 3,350
Resolution 1.56 Å R-free 0.211
9H02 Crystal structure of human CREBBP histone acetyltransferase domain in complex with a bisubstrate inhibitor, Lys-CoA Deposited 2024-10-07 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1322–1555（234 aa）
Chain A 1618–1700（83 aa）
Mutation：Y1503F Mutation：Y1503F 01K [(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]methyl (3R,20R)-20-carbamoyl-3-hydroxy-2,2-dimethyl-4,8,14,22-tetraoxo-12-thia-5,9,15,21-tetraazatricos-1-yl dihydrogen diphosphate × 1 EDO 1,2-ETHANEDIOL × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；291 K；0.1M (NH4)2SO4, 0.1 Na3 cit 5.6pH, 30% w/v PEG 4000
Resolution 2.03 Å R-free 0.224
9H0K Crystal structure of human CREBBP histone acetyltransferase domain in complex with Propionyl- Coenzyme A Deposited 2024-10-08 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1322–1555（234 aa）
Chain A 1618–1700（83 aa）
Mutation：Y1503F Mutation：Y1503F 1VU propionyl Coenzyme A × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；292 K；0.1M Na3 cit , 2.4M (NH4)2SO4
Resolution 1.75 Å R-free 0.240
9H0K Crystal structure of human CREBBP histone acetyltransferase domain in complex with Propionyl- Coenzyme A Deposited 2024-10-08 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 1322–1555（234 aa）
Chain B 1618–1700（83 aa）
Mutation：Y1503F Mutation：Y1503F 1VU propionyl Coenzyme A × 1 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；292 K；0.1M Na3 cit , 2.4M (NH4)2SO4
Resolution 1.75 Å R-free 0.240
9IWL X-ray structure of human PPARalpha ligand binding domain-intrinsic fatty acid (E. coli origin)-CBP coactivator peptide co-crystals obtained by cross-seeding Deposited 2024-07-25 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 62–80（19 aa）
Not recorded PLM PALMITIC ACID × 1 GOL GLYCEROL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；277 K；0.1M Tris (pH 8.5), 30% PEG 4000, 0.2M Sodium acetate trihydrate
Resolution 2.09 Å R-free 0.236
9J6O Crystal Structure of bromodomain of human CBP in complex with the inhibitor CZL-046 Deposited 2024-08-16 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1081–1197（117 aa） Fragment：UNP RESIDUES 1081-1197
Not recorded A1L3S (3~{S},5~{S})-1-[3,4-bis(fluoranyl)phenyl]-5-[5-(3,5-dimethyl-1,2-oxazol-4-yl)-1-(4-methoxycyclohexyl)benzimidazol-2-yl]-3-fluoranyl-pyrrolidin-2-one × 1 CL CHLORIDE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；277 K；0.2 M Potassium sulfate, 20% w/v Polyethylene glycol 3,350
Resolution 2.67 Å R-free 0.290
9JUU X-ray crystal structure of Y16515 in CBP Deposited 2024-10-08 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1081–1197（117 aa）
Not recorded A1EDN (5~{S})-1-(3-chloranyl-4-methoxy-phenyl)-5-[4-(3-methyl-1,2-benzoxazol-5-yl)-1-[(2~{R})-2-morpholin-4-ylpropyl]imidazol-2-yl]pyrrolidin-2-one × 1 EDO 1,2-ETHANEDIOL × 1 GOL GLYCEROL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 6.5；277 K；0.2 M Sodium citrate tribasic dihydrate, 0.1 M Sodium cacodylate trihydrate pH 6.5, 30% v/v 2-Propanol
Resolution 1.48 Å R-free 0.219
9JUY X-ray crystal structure of Y16513 in CBP Deposited 2024-10-08 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1081–1197（117 aa）
Not recorded A1EDO (5~{S})-1-(3-chloranyl-4-methoxy-phenyl)-5-[4-(3-methyl-1,2-benzoxazol-5-yl)-1-[(2~{S})-2-morpholin-4-ylpropyl]imidazol-2-yl]pyrrolidin-2-one × 1 DMS DIMETHYL SULFOXIDE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；277 K；0.2 M Sodium citrate tribasic dihydrate, 20% w/v Polyethylene glycol 3,350
Resolution 1.42 Å R-free 0.227

135 other PDB entries and 224 assemblies. Open the comparison page and filter oligomeric states

View Construct and Data Evidence
UniProt name CBP_HUMAN
Isoform —
PDB entities 2
Chains and sequence ranges Author chain C； PDBConstruct 1–47； UniProt 2065–2111 Author chain D； PDBConstruct 1–47； UniProt 2065–2111

The page prioritizes protein identity, the current assembly, associated components, oligomeric state and cross-PDB links. Chain mapping and sequence ranges are retained as data evidence. Internal IDs, import timestamps and assembly operation expressions are maintenance fields and are not shown here.

SAXS scattering curve SAXS Profile

SAXS profile for 7jfl

P(r) Distance Distribution P(r) Distribution

P(r) distribution for 7jfl
Download Download
▼

2. Structure Basics 2. Structure Basics

Entry ID entry_id7jfl
Deposition date deposition_date2020-07-17
Structure title titleCrystal structure of human phosphorylated IRF-3 bound to CBP
Keywords keywordstranscription factor, phosphorylation, innate immunity, IMMUNE SYSTEM; IMMUNE SYSTEM
Experimental Method methodX-RAY DIFFRACTION
▼

3. SAXS Parameters (CRYSOL theoretical calculation) 3. SAXS Parameters (CRYSOL)

Radius of gyration Rg (Guinier) rg_guinier24.41 Å
Radius of gyration Rg (electron density) rg_electron23.45 Å
Forward intensity I(0) i044364600.00
Molecular weight molecular_weight51779.0 kDa
Excluded volume excluded_volume64918 ų
Envelope volume envelope_volume77016 ų
Hydration-shell volume shell_volume27077 ų
Envelope diameter envelope_diameter77.5 Å
Shell Rg shell_rg30.79 Å
Envelope Rg envelope_rg23.46 Å
Shape Rg shape_rg23.42 Å
Total Rg total_rg24.39 Å
Total atoms total_atoms3646
Residues n_residues462
Spherical-harmonic order n_harmonics20
q range q_range— – 0.5000 Å−1
Data points n_points101
Shell type shell_typedirectional
Solvent electron density solvent_density0.3340 e/ų
Shell contrast contrast_shell0.0300 e/ų
CRYSOL version crysol_version4.1.3
▼

4. P(r) Distance Distribution (GNOM inversion) 4. P(r) Analysis (GNOM)

Maximum dimension Dmax dmax76.9 Å
Rg (real space) rg_real24.29 Å
Rg uncertainty (real space) rg_real_error0.41 Å
I(0) (real space) i0_real4.4360e+07
I(0) uncertainty (real space) i0_real_error4.9140e+05
Rg (reciprocal space) rg_reciprocal24.32 Å
I(0) (reciprocal space) i0_reciprocal44370000.0000
Solution quality estimate total_estimate0.9051
Solution quality rating solution_quality EXCELLENT a EXCELLENT solution
P(r) peaks n_peaks2
Primary peak position r_peak_primary28.1 Å
Skewness Skewness skewness0.181
Kurtosis Kurtosis kurtosis-0.531
Angular range angular_range— – 0.3250 Å−1
Current regularization parameter α current_alpha0.0000
Highest regularization parameter α highest_alpha17920000.0000
Real-space data points n_real_points64
GNOM version gnom_version4.1.3
Quality Criteria quality_criteria AN1: 0.000; Oscil: 0.926; Stabil: 1.000; Sysdev: 1.000; Positv: 1.000; Valcen: 1.000; Smooth: 0.983
▶

5. Crystallography and Experiment 5. Crystallography & Experiment

▶

6. Entities and Polymers Entities & Polymers (3)

▼

7. Fold Classification (SCOP + CATH) 2 domains

SCOP 2.08 (2 domains)

Domain ID domain_idd7jflc_
Class classa — All alpha proteins
Fold Fold folda.153 — Nuclear receptor coactivator interlocking domain
Superfamily Superfamily superfamilya.153.1 — Nuclear receptor coactivator interlocking domain
Family Family familya.153.1.1 — Nuclear receptor coactivator interlocking domain
Domain ID domain_idd7jfld_
Class classa — All alpha proteins
Fold Fold folda.153 — Nuclear receptor coactivator interlocking domain
Superfamily Superfamily superfamilya.153.1 — Nuclear receptor coactivator interlocking domain
Family Family familya.153.1.1 — Nuclear receptor coactivator interlocking domain
▶

8. Citations (1)

▶

9. Files and Curves (10)